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ABSTRACT 
Bile acids are one group of steroids that can be metabolically transformed by human 
gut anaerobes. One of these transformations is the conversion of primary bile acids to 
secondary bile acids by 7a-dehydroxylating gut bacteria such as Clostridium scindens, 
Clostridium hylemonae, and Clostridium hiranonis. These anaerobes metabolize bile acid 
derivatives via 3a- and 7a-hydroxysteroid dehydrogenases (HSDH). Studies to date have 
not reported if these organisms are capable of converting 12-oxolithocholic acid (12-
oxoLCA) to deoxycholic acid (DCA). The emphasis of this study was to determine the 
ability of C. scindens ATCC 35704, C. hiranonis DSM 13275, and C. hylemonae DSM 
15053 to reduce 1 2-oxoLCA to DCA during growth, to identify 1 2a-HSDH genes in, C. 
scindens and C. hiranonis, to express, purify, and characterize the 12a-HSDH gene product 
(protein) of C. scindens. These organisms were grown anaerobically at 37°C in brain heart 
infusion (BHI) broth. Bile acids, prepared in methanol, were added to BHI broth to a final 
concentration of 0.1 mM. Following growth, cultures were extracted with ethyl acetate; 
extracts were dried, re-suspended in methanol, and subjected to thin-layer chromatography 
(TLC) for the detection of bile acids. In addition, 12a-HSDH recombinant enzymes were 
characterized and purified by affinity chromatography using Strep-Tactin® resin. Kinetic 
constants (Km, Kca1, V max, and KcatlKm) were determined for the purified recombinant 
proteins for the forward and reverse directions. Catalytic efficiencies KcatlKm toward the 
reductive direction were between 2.8-3.5-fold greater than oxidative direction. However, 
V max and Kca1 in the oxidative direction were between 1 .6-2.9-fold higher than the reductive 
direction. The 1 2a-HSDH recombinant enzyme from each strain was shown to reduce 12-
oxoLCA to DCA. Moreover, these organisms were able to transform other oxo-bile acids 
during growth. 
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1. LITERATURE REVIEW 
The role of gut microbiota in human health. The role of the human microbiota has 
become widely appreciated, and the variation of bacterial types and the balance of some 
species are known to play a significant role in human health (1). The human gut contains 
over 1 ,000 species and 15,000 bacterial strains, all categorized under 9 phyla (2). Studies 
have shown that between individuals there are differences that often exist between three 
genera (types) of bacteria, Bacteroides, Prevotella, and Ruminococcus (3). Based on these 
types of dominant bacteria in each individual, people will be more or less likely to develop 
particular diseases(4, 5). Therefore, the composition of a person's microbiome can 
ultimately determine potential health problems (e.g., cancer, immunity, and bowel 
diseases) for the individual (6). These microbiomes create a beneficial relationship with 
the host by supporting gut homeostasis, developing the intestinal epithelium cells, 
protecting against pathogens, and supporting host immunity (7). All of these microbial 
occupations allow gut microbiota to regulate very essential and vital functions within the 
host physiology (7). It is important to know that bacterial populations dominate the 
microbiota in the human intestinal tract. Thus, it is critical to investigate the different 
factors that might influence the interaction of the gut bacteria and how they impact such 
host functions as immunity, mood, and bile acid metabolism (8). Anaerobic 
microorganisms are the main colonizers of the human gut. Consequently, most studies 
have been focused on Bacterial genera such as Clostridium, Veillonella, Ruminococcus, 
Eubacterium, Bifidobacterium, lActobacillus, Fusobacterium, Peptococcus and 
Peptostreptococcus, as they have been considered to be the dominant gut microbes 
(Figure 1 ), (9-11 ). 
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Fig 1. Diversity and populations of bacteria in different parts of the human 
gastrointestinal can tract (58). 
Bile acids chemistry. Bile acids, are defined as a group of steroids that synthesized 
in the Liver via cholesterol and conjugated to the amino acid glycine and taurine, stored in 
the gallbladder and secreted into the lumen( I 2, 13). The conjugated bile acids are the 
major solutes in human bile (14). The synthesis of primary bile acids cholic acid (CA) and 
chenodeoxycholic acid (COCA) multifaceted and requires about 17 individual enzymes, 
these enzymes occur in multiple intracellular parts that include the cytosol, endoplasmic 
reticulum, mitochondria, and peroxisomes ( 13, 14 ) . Before the primary bile acids are 
secreted into the canalicular lumen they are conjugated via an amide bond at the terminal 
carboxyl group with amino acids glycine or taurine (14). These conjugation reactions yield 
glycoconjugates and tauroconjugates, respectively (14). This conjugation process 
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increases the arnphipathic nature of the bile acids making them more easily secret-able as 
well as less cytotoxic (14). 
Large amounts of bile acids are secreted into the human intestine every day; about 
95% of bile acids reach the duodenum and are absorbed across human intestinal and then 
recycled back to the liver(13). Only 5% continues to travel to the colon and is ultimately 
discharged through defecation(l5). The bile acids not absorbed (5%) are subject to 
metabolism by the gut microbiota. One of the main reactions catalyzed by the gut 
microbiota is the transformation of primary bile acids CA and COCA into secondary bile 
acids deoxycholic acid (DCA) and lithocholic acids (LCA), respectively. It is significant 
to indicate that cholecystok.inin is the hormone that responsible for the secretion of the bile 
into the intestine, and this secretion is stimulated by the presence of fat in the duodenum 
( 16). DCA absorbed in the colon enters enterohepatic circulation whereas LCA is insoluble 
and only a small amount of this secondary bile acid is reabsorbed ( 17, 18). 
As a metabolic regulator, it has become clear that bile acids are also signaling 
molecules, the function of bile acids in regulating lipid and glucose homeostasis are 
appeared as ; i) bile acids and phospholipids solubilize cholesterol in the bile, which 
prevents the precipitation of cholesterol in the gallbladder; ii) bile acids facilitate the 
digestion of dietary triacylglycerols by acting as emulsifying agents that render fats 
accessible to pancreatic lipases; iii) enable the intestinal absorption of fat-soluble vitamins 
(14, 19). 
Relative to the intra and extracellular activity of bile acids in the host, the binding of 
bile acids to FXRs attenuated the expression of many genes that are associated with bile 
acid homeostasis (14, 19). In addition to the roles of bile acids in lipid emulsification in 
the intestine and activating FXR, bile acids also participate in some signaling transduction 
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such as; i) activating c-JUN N- terminal kinase (JNK); ii) activate mitogen-activated 
protein kinase (MAPK) pathways are ligands for the G-protein-coupled receptor (GPCR) 
TGR5; and iii) activates nuclear hormone receptors such as famesoid X receptor a (FXRa; 
NR1H4) (14, 20). 
Bile acid toxicity. Bile acids are amphipathic molecules possessing both hydrophilic 
and hydrophobic parts (21 ). This explains how bile acids act as a detergent by solubilizing 
and transporting fat molecules for absorption ( 18). Bile acids also play a role in numerous 
physiological capacities, for example, processing and assimilation of lipids and lipid­
solvent supplements in the intestinal lumen, control against bacterial excess, and disposal 
of cholesterol from the body (21). Relative to toxicity, bile acids can damage cellular 
DNA and lead to carcinogenesis, and DCA at high levels (-100 µM) can promote 
apoptosis in the epithelial cells (22). The continual damage of DNA will increase the 
mutation rate; hence, increased levels of bile acids are a major factor associated with 
pancreas and colon cancers in humans ( 17). Normally, during the physiological process, 
there is no metabolic pathway for the removal of the DCA from the bile acids pool. 
Toxicity of secondary bile acids is elevated by the dysbiosis of gut microbiota and that 
occurs when anaerobic bacteria such as, C. scindens, C. hylemonae, C. hiranonis, 
transformed many forms of oxo-bile acid derivatives to secondary forms (23). 
Consequently, high level of bile acids in the gut can suppress the growth of other 
commensal bacteria and boost the dysbiosis rate, that will lead to serious illnesses like 
metabolic syndrome, irritable bowel diseases, and cancers (17-18). 
Diet and bile acids. The gut is the largest organ in the body, and the human 
microbiome is made out of trillions of microscopic organisms (9, 25). Consuming fatty 
food, animal protein diet, alcohol and smoking routine, can alter the composition of 
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microorganisms in the gut (25). Comparable to other chronic diseases, dietary fat intake 
appears to be one of the most influential risk factors in progression of gut cancers (26). 
Synthesis of bile acids. Bile acids are known as the end product of the utilized 
cholesterol, in fact, this synthesis is the major pathway of cholesterol catabolism in human 
(14). Even though different enzymes involved in bile acids synthesis are found in different 
types of cells, the liver considers as the only organ that allow the biosynthesis of this 
enzymes to completely occur (14). The initiation of the bile acid synthesis in the liver 
occurs by cholesterol 7a-hydroxylase (CYP7 Al) enzyme, and the synthesis of the CA and 
the ratio of CA/CDCA are regulated by sterol 12a-hydroxylase (CYP8Bl) enzyme (14, 
15). Both (CYP8Bl) and (CYP7Al) are regulated by bile acids via feedback repression 
mediated by farnesoid X receptor (FXR)-dependent induction of fibroblast growth factor 
15/19 (FGF15/ 19) in the intestines (14, 15). FGF15/19 binds to FGF receptor 4/P-Klotho 
complex in hepatocytes which activates the JNKI/2 and ERKI/2 signaling cascade, down­
regulates (CYP7 Al) mRNA expression in the liver (15, 19). In the inner mitochondrial 
membrane, hydroxylation of cholesterol at the 27 position, acidic pathway initiated by 
mitochondrial sterol-27-hydroxylase (CYP27 Al), in many tissues, (CYP27 Al) is 
expressed extra-hepatically (14, 15). At the normal physiological condition, the acidic 
pathway is considered to be a minor pathway for bile acids synthesis and its accounts no 
more than 6%, however, in patients with cholesterol liver disease, the acidic pathway 
appears to be predominant pathway in synthesizing bile acids as (CYP7 Al) is down 
regulated by the inflammation of small bowel in these patients (15, 19). 
Humans, unlike rodents, are incapable to make 7-hydroxylating secondary bile acids 
back to the liver during the enterohepatic circulation, thus secondary bile acids in some 
humans can approach 60% of the biliary pool (15). Once the bile acids enter the terminal 
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ileum and proximal colon, instantly they are conjugated by prokaryotic enzymes known as 
bile salt hydrolase (BSH) (15). This enzyme, BSH, has different an affinity to taurine or 
glycine conjugates, BSH found in several bacterial divisions, such as 30% of Firmicutes, 
14.4% of Bacteroides, and 8.9% of Actinobacteria (14). The detoxication function of BSH 
is reducing the bile salt level from the colon environment (14, 15). 
Bile acid-dehydroxylating bacteria. Roughly, 400 to 800 mg per day of bile acids 
enter the intestinal, and most of this amount is transformed into different bile acids forms 
(12). Anaerobic gut bacteria are responsible for many transformations of bile acids within 
the human gut (27). Clostridium scindens has been reported to be capable of 7a­
dehydroxylation. this activity converts CA and CDCA to deoxycholic acid (DCA) and 
lithocholic acid (LCA), respectively. In general, Clostridium species that produce 7aJP­
dehydroxylation enzymes involved in bile acid metabolism include C. scindens and C. 
hiranonis, which belong to Clostridium cluster XIVa group, C. sordelli and C. 
biofermentans, which belong to Clostridium cluster XI group, and C. leptum which belongs 
to Clostridium cluster IV group (4, 28-30). Low dehydroxylation activity has been found 
in C. hylemonae, C. sordelli, C. biofermentans, and C. leptum; however, other Clostridium 
species are identified as highly active in bile acid dehydroxylation such as C. scindens and 
C. hiranonis (29, 30). 
Genes involved in dehydroxylation. The following are known genes involved in the 
dehydroxylation of bile acids: 
a. baiA gene: A 27-kDa polypeptide containing 249 amino acids is encoded by 
baiA gene and resembles the short-chain alcohol/polyol dehydrogenase gene family (31, 
32). In C. scindens, different types of baiA genes have been found such as baiAJ and baiA, 
which are identical, while baiA2 is associated with the bai operon (31, 32). 
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b. baiB gene: A 58-kDa polypeptide with 521 amino acids encodesa. CoA ligase, 
which depends on ATP, CoA, and Mg2+ and catalyzes the synthesis of CoA conjugated bile 
acids (31, 32). 
c. baiCD gene: A -70-kDa polypeptide that encodes a steroid oxidoreductase enzyme, 
and this enzyme requires NAD+ or NADP+ for its activity (31, 32). 
d. baiH gene: A -72 kDa-polypeptides with 661 amino acids is encoded by the 
baiH gene and is a steroid oxidoreductase. In C. scindens, the steroid oxidoreductase 
produced by baiH gene is specific for 3-dehydro-4-ursodeoxycholenoic acid and 3-
dehydro-4-epicholenoic acid conjugated with CoA (31, 32). 
e. baiF gene: A 47.5-kDa polypeptide comprising 426 amino acids is encoded by the 
baiF gene (13). Bile acid CoA hydrolase activity bas been found as a product from this 
gene (31, 32). 
f baiG gene: A 50-kDa polypeptide containing 477 amino acids is encoded by this 
gene, and the transport of free primary bile acids, CA and COCA, is facilitated by the 
baiG gene product; however, the secondary bile acids are not transported (31, 32). 
g. baiE and bail genes: A -19 .5-kDa polypeptide holding 166 amino acids is encoded 
by baiE gene, and the enzyme encoded by this gene forms the stable intermediates 3-
dehydro-4,6-deox ycholdienoic acid and 3-debydro-4,6-lithocholdienoic acid, respectively. 
The bail gene sequence shows homology with the baiE gene which indicates that bail gene 
encodes the bile acid 7P-dehydratase (31, 32). 
The removal of 7a.-bydroxy group from primary bile acids requires multiple steps 
(Figure 2), and these steps include: ligation to CoA by baiB gene, oxidation of 3a.-hydroxy 
by baiA gene, oxidation of C-4 and C-5 by baiCD gene, and 7a.-hydroxy by baiE gene. All 
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of these reaction will be followed by consecutive reductions of NADP(H) at C-6- C-7, C4-
C5, and 3-oxo followed by export of secondary Bile acids (15). Once bile acids enter the 
gut, metabolic activity will take place by variety of facultative and anaerobic bacteria, such 
as Lactobacillus, Streptococcus, Staphylococcus, Escherichia, Enterococcus, Clostridium, 
and Bacteroides (31 ). 
Oxidation, reduction, and epimerization reactions. Microbial secretion of the 
hydroxysteroid dehydrogenase (HSDH) enzymes can oxidize and epimerize 3, 7, and 12-
hydroxy groups of bile acids in the gastrointestinal tract (15, 33-35). 
Epimerization of bile acids hydroxy group is a chemical conversion of one epimer to 
another in stereochemistry from a to p configuration with the generation of a stable oxo­
bile acid intermediate. The epimerization reaction needs to occur, (6, 31, 36). This 
reaction happens as a microbial metabolic process on the steroid molecule (32). The 
intraspecies epimerization performed when one species metabolize either a-HSDH or P­
HSDH of the hydroxyl group; however, the interspecies occurs when reaction happens on 
both a-HSDH and P-HSDH site by different species at the same time (31, 36). The 
reversible oxidation and reduction reactions depend on the redox of the environment, 
production of oxo-bile acids is more favorable at the higher redox potentials found on the 
mucosal surface, whereas the reduction of the oxo-bile acids might be more favorable 
under the low redox potentials in the large intestinal lumen (31). 3a IP HSDHs have been 
detected in most intestinal bacteria to catalyze the reversible oxidation/ reduction between 
3-oxo- bile acids and 3a or 3p-hydroxy bile acids (34). Besides, 7a IP HSDHs are also 
common among the intestinal bacteria, however, the presence of the 7a IP-dehydrogenation 
is difficult to explain due to the irreversible of the 7a IP-dehydrogenation of bile acids (34 ). 
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In general, HSDHs have different reductive and oxidative pH optima, NAD(H) or 
NADP(H) requirements, molecular weight, and gene regulation (34). 
12a-hydroxysteroid dehydrogenase HSDHs. HSDHs are found in a wide variety of 
microorganisms including bacteria and archaea, suggesting that steroid metabolism is an 
evolutionarily conserved mechanism that might serve different functions(12). There were 
only few studies reported that 12a-HSDH enzyme was actively found in Clostridium group 
P, strain C 48-50 ATCC 29733 (37). Although the 12a.-hydroxy oxidation/reduction was 
observed in Clostridium group P, the epimerization to 12P-hydroxyJ group was confirmed 
in Clostridium paraputrificum D 762-06 (38). 12a.-HSDH was mainly found in C. 
perfringens, C. Leptum, Eubacterium Lentum, Clostridium tertium, Clostridium difficile, C. 
paraputrificum and crude preparation of Pseudomonas (31, 37, 38). Though bile acids 
generate up to 27 derivatives, up to date, it has not been reported that 12-oxolithochoJic 
acid ( 12-oxoLCA) is able to be transformed by anaerobic gut bacteria to DCA (39). 
Consequently, it is significant to dedicate a study to understand the concept of potential 
transformation of 12-oxoLCA to DCA besides other oxo-bile acids derivatives by some of 
Clostridium spp. such as C. scindens, C. hiranonis, and C. hylemonae. 
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Fig 2. Biochemical pathway representing multiple steps involved in transforming of 
cholesterol to the primary bile acid chenodeoxychoJic acid (CDCA) in the human liver, 
and the conversion of CDCA to lithocholic acid (LCA) in the human gut via anaerobic 
bacteria. Bacterial genes in the figure have been identified in Clostridium scindens A TCC 
35704 (15). 
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2. OBJECTIVES 
The objectives of this study were to: 
• Determine the ability of C. scindens ATCC 35704, C. hiranonis DSM 13275, and 
C. hylemonae DSM 15053 to reduce 12-oxolithocholic acid (12-oxoLCA) to 
deoxycholic acid (DCA) during growth (Fig 3). 
• Identify the presence of a 12a.-HSDH gene in C. scindens ATCC 35704. 
• If present, express, purify, and characterize the 12a.-HSDH gene product (protein) 
of C. scindens A TCC 35704. 
OH 
12-oxolithochollc acid 
2[H] 
NADPH NADP-
OH 
H 
Dco\.ycholic acid 
Figure 3. Conversion of l 2oxolithocholic acid to deoxycholic acid by anaerobic 
gut bacteria. 
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3. MATERIALS AND METHODS 
Bacterial strains. Clostridium scindens ATCC 35704, Clostridium scindens VPI 
12708, Clostridium hiranonis DSM 13275, and Clostridium hylemonae DSM 15053 were 
obtained from Dr. Steven L. Daniel's culture collection at Eastern Illinois University and 
were revived from -80°C glycerol stocks. 
Culture conditions and growth studies. Brain heart infusion (BHD broth was the 
sole culture medium used for the cultivation of the bile acid-metabolizing bacteria used in 
the current study. BHI broth (200 ml) consisted of the following: 7.4 g brain heart 
infusion; 1.0 g yeast extract (Fisher Scientific); 0.4 g glucose (dextrose); 0.2 ml 0. 1 %  
resazurin; 1.5 g sodium bicarbonate. All components were added to a 500-ml Erlenmeyer 
flask containing a stir bar, thoroughly mixed, and brought to a boil (-15 min). After 
reaching a hard boil, the medium was gently bubbled with C02 until the medium color 
became brightly pink. Once the medium color reached a light pink in color, the medium 
was cooled in an ice bath while bubbling with C02. After the medium was cooled, 0.1 g 
of cysteine •HCl•H20 was added to the medium; bubbling was stoppered, and the 
headspace of the flask was flushed with C02. Once the medium became colorless, 10 ml 
was dispensed into 18 x 150-mm crimp-seal Bellco culture tubes (Belko Glass, Inc., 
Vineland, NJ, USA) which were being flushed with C02. Tubes were stoppered and sealed 
with aluminum crimp seals and then autoclaved at 121°C for 15 min with fast exhaust. The 
pH of the medium after sterilizing and cooling was 6.6-6.8. In all experiments, sterile 
culture media were inoculated aseptically with 0.5 ml of inoculum using sterile 1.0-ml 
syringes and sterile 23-gauge needles. Inoculated tubes were incubated vertically in the 
dark at 37°C without shaking. 
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For growth studies done in the presence of individual bile acids (Table l )  or in the 
presence of a combination of two different bile acids (i.e., CA/DCA; CA/12oxoCDCA; 
and CA/12-oxoLCA), sterile bile acid stock solutions (10.6 mM per bile acid; see below 
for preparation and use) were added (0.1 ml) via sterile 1 .0-ml syringes and sterile 23-
gauge needles to tubes of sterile BHI broth ( 10  ml) prior to inoculation. Following 
inoculation, final concentration of a bile acid added to BHI broth was 0 . 1  mM. 
For growth studies done in the presence of bile acids and potential regulatory 
substrates (Table 2), sterile substrate stock solutions (540 mM per substrate; see below for 
preparation and use) were added (0.2 ml) via sterile 1.0-ml syringes and sterile 23-gauge 
needles to tubes of sterile BHI broth ( 1 0  ml) prior to inoculation. Following inoculation, 
final concentration of a bile acid added to BHI broth was 10 mM. 
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Table 1. Preparation of bile acid solutions used in this study 
Molecular weight Stock solution (g of bile acid per 
Bile acida 
(g/mol) 10 ml of methanol; 10.6 mM) 
CA 430.60 0.045644 
3-oxoCA 406.56 0.043095 
7-oxoDCA 406.56 0.043095 
12-oxoCDCA 406.56 0.043095 
DCA 414.6 0.043948 
12-oxoLCA 390.56 0.041399 
3-oxoDCA 390.56 0.041399 
3, 12-dioxoLCA 388.54 0.041185 
7, 12-dioxoLCA 404.54 0.042881 
3, 7, 12-trioxoLCA 402.52 0.042667 
a Bile acids used in this study: sodium cholate (CA); 3-oxocholic acid (3-oxoCA); 7-
oxodeoxycholic acid (7-oxoDCA); 12-oxochenodeoxycholic acid (12-oxoCDCA); 
deoxycholate (DCA); 12-oxolithocholic acid (12-oxoLCA); 3-oxodeoxycholic acid (3-
oxoDCA); 3, 12-dioxolithocholic acid (3, 12-dioxoLCA); 7, 12-dioxolithcholic acid (7, 
12-dioxoLCA); and 3, 7, 12-trioxolithocholic acid (3, 7, 12-trioxoLCA). 
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Table 2. Molecular weight of different potential regulatory substrates used in this 
study 
Substrate 
Sodium nitrate (NaN03) 
Pyruvic acid (C3H403) 
Sodium formate (NaHC02) 
Sodium thiosulfate (NaS203) 
H2 
Molecular weight Stock solution (g of substrate per 
{g/mol) 
84.99 
88.60 
68.01 
248. 18 
1.01 
1 00  ml of DRO water; 540 mM) 
4.58946 
4.7844 
3.67254 
13.40172 
NA3 
a NA, not applicable. 5 ml of H2 gas was used per 10 ml of medium. Molar volume of 
a gas equals I mmole per 22.4 ml at STP; 5 ml of H2 gas therefore equals 
approximately 0.22 mmoles per 10 ml or 22 mmoles per liter (22 mM). 
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Stock solutions. (i) Bile acids. A stock solution ( 1 0.6 mM) of each bile acid was 
prepared based on the following equation: molecular weight (g/mol) of bile acid x 0.0106 
moles/liter x 0.01 liters = g of bile acicl/10 ml of methanol (Table 1 ). Bile acid solutions 
were filtered using sterile 0.2-µm, 25-mm nylon syringe filters and sterile 10-ml syringes. 
Filtered methanolic solutions were aseptically transferred to sterile tubes, stoppered with 
sterile butyl rubber stoppers, crimp sealed and then made anoxic by flushing and 
pressurizing with argon gas. Anoxic stock solutions were stored at room temperature. 
(ii) Potential regulatory substrates. Several substrates were examined their potential 
impact (i.e., regulation) on the reductive conversion of 12-oxoLCA to DCA. In other 
words, this experiment was designed to determine if sodium thiosulfate or sodium nitrate 
could serve as an alternative electron acceptor (i.e., reductant sink), thus decreasing 12-
oxoLCA reduction to DCA. Furthermore, pyruvate, H2 gas, and formate are known end 
products of glucose fermentation by C. scindens A TCC 35704 (reference needed) and were 
thus used to assess their ability to potentially regulate (e.g., via feedback inhibition) 12-
oxoLCA transformation. All of the potential regulatory substrates were prepared as sterile, 
anoxic 540 mM stock solutions (Table 2); H2 was tested by aseptically injecting 5 ml of 
gas into the headspace of tubes containing l 0 ml of medium. 
(iii) Mono-oxo bile acid TLC solvent system. The solvent system used to clearly 
visualize the mono-oxo bile acids (CA, 3-oxoCA, 7-oxoDCA, 1 2-oxoCDCA, DCA, 12-
oxoLCA, and 3oxo-DCA) was cyclohexane, ethyl acetate, and glacial acetic acid at a ratio 
of 12: 12: l (v/v/v), respectively. 
(iv) Di- and tri-oxo bile acid TLC solvent system. The solvent system used to for 
di- and tri-oxo bile acids (3, 1 2-dioxoLCA; 7, 1 2-dioxoLCA; and 3, 7, 1 2-trioxoLCA) was 
toluene, 1-4 dioxane, and glacial acetic acid at a ratio of 70:20:2 (v/v/v), respectively. 
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(v) Charring agent. Charring agent (500 ml) was used in TLC analysis for the 
visualization of bile acids on TLC plates and consisted of methanol ( 150 ml), water ( 150 
ml, concentrated H2S04 ( 10  ml), and MnCh•4H20 ( 1  g). Charring agent solution was 
stored at room temperature. 
(vi) Buffering agents. Streptavidin-binding buffer was prepared for use in the protein 
purification process and consisted of 2.42 g Tris base (20 mM), 8.78 g NaCl ( 1 50 mM), 
100 ml of glycerol (10% glycerol), and 900 ml of distilled water. Elution buffer 
(QIAGEN) used in the affinity chromatography to wash the protein from the unbound 
proteins and release the desired protein from the ligand. For elution buffer, the recipe was 
1 5  ml of streptavidin-binding buffer containing 0.00834 g d-desthiobiotin (2.5 mM). Other 
buffering agents used for pH optimization in the kinetics analysis of the recombinant 
enzyme included: citrate (pH 3.25 and 4), acetate (pH 4.5, 5.25, and 6), Tris-Cl (pH 8, 8.5, 
and 9), and glycine (pH 10 and 1 1). For enzymatic assays, all substrates such as CA; 3-
oxoCA; 7-oxoDCA; 12-oxoCDCA; DCA; 12-oxoLCA; 3oxo-DCA; 3, 12-dioxoLCA; 7, 
12-dioxoLCA; and 3, 7, 12-trioxoLCA were dissolved in methanol. All co-factors like 
NADP+ and NADPH were dissolved in water, and 12a-HSDH enzyme was diluted in 
buffer with the correct pH for the direction of the reaction being tested. For GeJ 
electrophoresis, 1 X of electrophoresis running (T AE) buffer, consisting of 40 mM Tris, 20 
mM acetate and l mM  EDTA in I liter of DI water, was used to run the gel electrophoresis 
to confirm the correctness of the DNA transformants. 
Thin-layer chromatography (TLC). Thin-layer chromatography (TLC) (Whatman 
AL SIL G, 20 x 20 cm, 250 µm thick, non-UV) was used to detect bile acids (see Table 1 )  
in standards ( 1 00  µM) prepared with 100% methanol, i n  standards ( 1 00  µM) prepared with 
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sterile BHI broth, and in cultures. The starting concentrations of all bile acids in cultures 
approximated 1 00  µM. 
To detect bile acids in stationary-phase culture fluids, 1-ml samples of cultures were 
aseptically removed via sterile 1 .0-ml syringes and sterile 23-gauge needles and transferred 
into two 2-ml microfuge tubes (0.5 ml of culture per microfuge tube). Each 0.5-ml sample 
was acidified by adding 100 µI of 3 N HCI and mixed by vortexing. To extract the bile 
acids from culture media, ethyl acetate (500 µl) was added to each acidified sample, and 
the microfuge tubes were capped, vortexed, and spun in a microcentrifuge for 1 min at 
1 4,000 rpm. The upper organic phase which contained the extracted bile acids was 
carefully removed with a 1 -ml Eppendorf pipettor and transferred to a labeled, small, 
screw-capped, wide-mouth vial. The 0.5-ml acidified samples were extracted a second 
time with ethyl acetate (500 µl), and the second extracts were transferred to the same vial 
that received the first extracts. The combined ethyl acetate extracts were dried at room 
temperature under a stream of nitrogen; once dried, methanol ( 100 µl) was added to the 
wide-mouth vial and then capped and mixed to resuspend the dried extracts. Resuspended 
extracts were used immediately for TLC analyses. The same procedure was used for bile 
acid standards prepared in sterile BHI broth. All manipulations were done in a fume hood 
and while wearing protective glasses, gloves, and a lab coat. 
Resuspended extracts were spotted (50 µl) on a TLC plate at the designated spots; each 
spot was 3 cm from the bottom of the plate and 2.5 cm apart from one another and from 
the edge of the plate with a typical TLC plate allowing 7 samples to be analyzed at one 
time. With an Eppendorf pipettor and 100-µl tips, methanol-dissolved extracts were 
spotted onto TLC plates by applying a small amount of sample at a time, allowing that spot 
to dry, and then applying more of the sample in order to minimize creating a large sample 
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spot. In addition, to help quicken the spotting process and to reduce spot size, a hair dryer 
on low setting was used between applications in order to help accelerate methanol 
evaporation and sample drying. Theoretically, when initial bile acid concentrations were 
100 µM in standards or in cultures, the amount of bile acid per spot on a TLC plate was 
equivalent to approximately 50 nmoles of bile acid per 50 µI of resuspended extract spotted. 
Once all spots were dry, TLC plates were placed in a glass TLC chamber containing 
50 ml of the solvent specific to the bile acid category (mono, di, or tri; see solvent 
compositions above). Run times for TLC plates approximated 3 h; afterwards, plates were 
removed, and the leading edge of the solvent front marked on the plate with a pencil. Plates 
were subsequently thoroughly dried at room temperature in the fume hood and then sprayed 
over the entire surface with the charring agent (water, methanol, concentrated H2S04, and 
MnCh). Sprayed plates were dried in a small toaster oven for - 1 5  min at 1 50°C, observed 
under long wavelength UV light (365 nm) and photographed for future reference. Bile 
acids were identified by comparing Rr values of bile acids detected from cultures to Rr 
values of standard bile acids. Rr values represented the distance traveled in millimeters by 
the bile acid from the origin to the center of the bile acid spot divided by distance traveled 
in millimeters by solvent front from the origin to the leading edge of solvent front. 
Gene Cloning. (i) Polymerase chain reaction and DNA amplification. PCR was 
used to provide sufficient 12a-HSDH gene-containing segments of DNA from C. scindens 
ATCC 35704 for gene cloning. Genomic DNA was extracted for molecular cloning using 
the Fast DNA isolation kit from Mo-Bio (Carlsbad, CA, USA) as described in the 
manufacturer's protocol. The 1 2a-HSDH gene was amplified using Phusion High Fidelity 
Polymerase (Stratagene La Jolla, CA) as described by the manufacturer's protocol, and 
annealing time for the amplification was determined to be 63.3°C for C. scindens. PCR 
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reactions conditions are described in Table 3. Primers used in this study were obtained 
from Integrated DNA Technologies, Inc. (Coralville, IA, USA). 
(ii) Purification of the insert. PCR product was cleaned using a PCR purification Kit 
(Qiagen, Valencia, CA, USA), according to the manufacturer protocol. PB buffer (5X 
volume) was added to each PCR reaction (250 µ1 of PB buffer to 50 µl of reaction volume). 
The mixture was transferred to a spin column and centrifuged for 30 sec at 13,000 rpm. 
Flow through was discarded, and 750 µl of PB buffer was added and recentrifuged for 30 
sec at 1 3,000 rpm. Flow through was again discarded and the column recentrifuged for 
another 30 sec at 13,000 rpm to remove any extra fluid. Next, the column was placed in 
a microfuge tube, and 50 µI of H20 was added to the column. After 3 min, the column was 
centrifuged for 1 min at 1 3,000 rpm and the flow through collected. The concentration of 
DNA in the collected flow through was measured using Nanodrop (Fisher Scientific™). 
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Table 3. Amplification of 12a-HSDH gene 
Amount 
Component name (concentration in stock solution) added 
Molecular grade H20 35.5 µl 
5X Buffer 10 µl 
1 0  mM dNTP ( 1 0  mM) I µI 
Template DNA (C. scindens genome) I µl 
FWD primer (5'-forward primer-3') ( 10  µM) 
I µI 
ATATATGGTACCGATGGGTATATTTGACGGAAAAACAGCTA 
REV primer (5'-reverse primer-3') ( 1 0  µM) 
1 µI 
ATATATAAGCTTTTATGGGCGCTGTCCCATGC 
Phusion polymerase (20 units/ml) 0.5 µl 
Total volume 50 µI 
(iii) Recombinant DNA. PCR product and the pET5 1 b vector were double digested 
in order to insert the amplified DNA fragment of 1 2a-HSDH into the pET5 1 b  vector. The 
pET5 l b  vector was obtained from Novagen (San Diego, CA, USA). pET5 l b  vector was 
digested with the appropriate restriction endonucleases and treated with DNA ligase to 
allow a successful insertion of the target DNA 12a-HSDH. The double digestion run on 
the vector was applied by following the same PCR process explained by the manufacturer's 
protocol using the Phusion High Fidelity Polymerase (Stratagene La Jolla, CA). 
Restriction enzymes for C. scindens were Hindlll and BamHI, and the buffer used was 
Buffer 3 . 1 .  All restriction enzymes were obtained from NEB (Ipswich, MA). 
2 1  
(iv) Gel electrophoresis. Gel electrophoresis was applied to confirm the plasmid 
transformants. In 125 ml flask, 50 ml of 1 X TEA buffer was added to 500 mg of 
electrophoresis grade agarose, mixed then placed in a microwave for 30-45 sec. After the 
liquid had boiled, 5 µl of ethidium bromide was carefully added and mixed until dissolved. 
The appropriate size comb was placed into the gel tray, and the gel was poured into the 
tray gently and kept at room temperature for 20 min to solidify. Once solidified, the gel 
was placed into the gel electrophoresis apparatus, and T AE buffer ( 1 X) was added until it 
was about a half inch above the gel. Gels were loaded by placing 6 µl of DNA ladder in 
first well while the other wells were loaded by first mixing 1 µl of loading dye with 5 µl of 
PCR reaction product and then transferring the entire amount to a well, loading dye and 
DNA ladder were obtained from Thermo Fisher Scientific. Gels were run for I h at 120 
V, and results were visualized by Gel Doc. 
(v) Transformation of DHSa cells. The recombinant plasmids ( 12a-HSDH gene 
cloned into the pET-51 b ( +) vector) were transformed into Escherichia coli DH5a cells. 
DH5a cells were revived from glycerol stocks stored at -80°C. In microfuge tube, 2 µl of 
ligation product, (plasmid contains the gene of interest), was added to 25 µl of DH5a 
competent cells. Tubes containing competent cells with the ligated products were cooled 
in ice for 30 min then placed in the thermomixer for 40 sec at 43°C, then iced again for 5 
min. Aseptically, 200 µl of super optimal broth with glucose (SOC) medium was added to 
the mixture, tubes were placed in the shaker - 1 50 rpm for 1 h at 37°C. Each sample was 
transferred to Lysogeny Broth (LB) agar plate supplemented with ampicillin ( 100 µg/ml), 
and cells were spread over the agar surface and incubated overnight at 37°C. From each 
transformation, a single colony was picked with an Eppendorf tip, put into small conical 
tube containing 5 ml of LB broth supplemented with ampicillin ( I  00 µg/ml) and incubated 
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overnight with shaking (-250 rpm) at 37°C. Cells in cultures were harvested by pelleting 
at 1 0,000 rpm for 3 min; cell pellets of DH5a were stored at -80°C for plasmid extraction 
process. 
LB broth was the culture medium used for the growth of Escherichia coli DH5a cells 
and the overexpression of the recombinant plasmid. LB broth consisted of the following 
per liter: 10 g tryptophan, 5 g yeast extract, 5 g NaCl, and 15 g of agar when needed. All 
components were added to 2-1 flask, covered with aluminum foil, and then autoclaved at 
liquid cycle for 1 h at 1 2 1 °C. The medium was cooled to room temperature then aseptically 
supplemented with ampicillin (100 µg/ml of medium) and chloramphenicol (50 µg/ml of 
medium) as indicated. 
(vi) Plasmid extraction/purification and gel electrophoresis. The recombinant 
plasmid was extracted and purified according to the manufacturer protocol QIAprep Spin 
Miniprep Kit (Qiagen, Valencia, CA, USA). Gel electrophoresis (see protocol above) was 
applied to confirm the plasmid transformants. 
(vii) Gene sequencing. Sanger DNA sequencing was then used to determine the 
proper insertion of the gene into the plasmid and to verify the 12a-HSDH gene sequence. 
Sequencing and data analysis were done at the W. M. Keck Center for Comparative and 
Functional Genomics at the University of Illinois at Urbana-Champaign. 
Overexpression of the Recombinant Protein. (i) Transformation into BL-21 
CodonPlus. The extracted recombinant plasmids containing the cloned gene were 
transformed into E. coli BL-21CodonPlus (DE3) RIPL chemically competent cells by 
using heat shock method. BL-21 cells were revived from glycerol stocks stored at -80°C 
at University of Illinois at Urbana-Champaign. 
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In microfuge tube, lµl  of recombinant plasmid-containing solution was added to 30-
50 µl of BL-21 competent cells. Tubes containing competent cells and recombinant 
plasmid-containing solution were cooled in ice for 30 min then placed in the thermomixer 
for 40 seconds at 43°C, then iced again for 5 min. Aseptically, 200 µl of super 
optimal broth with glucose medium was added to the mixture, and tubes were placed on a 
shaker (-150 rpm) for 1 h at 37°C. Cells were grown on LB plates supplemented with 
chloramphenicol (50 µg/ml) and ampicillin ( 100 µg/ml) and incubated overnight at 37°C. 
(ii) Overexpression. Colonies were picked using sterile pipette tips and transferred 
to 10 ml of LB broth supplemented with chloramphenicol (50 µg/ml) and ampicillin ( 1 00  
µg/ml). Culture tubes were incubated for 6 h on a shaker (-250 rpm) at 37°C. The entire 
volume of a l 0-ml culture was transferred to a flask containing one liter of LB broth 
supplemented with chloramphenicol (50 µg/ml) and ampicillin ( 100 µg/ml). Flasks were 
incubated at 37°C on a shaker (-220 rpm) until growth (OD600nm) reached approximately 
0.3 (about 3 h). Recombinant protein production was then induced by adding 750 µl of 
isopropyl �-D-1 -thiogalactopyranoside (IPTG) to the LB cultures; flasks were incubated 
overnight at 16°C. Following overnight incubation, cells were pelleted in a preparative 
centrifuge for 30 min at 5,000 rpm and 4°C. Pelleted cells were then re-suspended in 30 
ml of cold binding buffer (pH 7.9) containing 20 mM Tris HCl, 150 mM NaCl, 10% 
glycerol, and 10 mM 2-mercaptoethanol. 
Enzyme Purification. (i) Cell lysis. Cells that induced with IPTG were treated by 
adding 25 µl of beta-mercaptoethanol B-ME and 25 µl of DNase were added along with 
750 µI of lysozyme to the same mixture, then tubes were vortexed to mix. After that, cell 
suspension was passed several times through an EmulsiFlex C-3 cell homogenizer 
(A vestin, Ottawa, Canada) according to manufacturer's protocol. Soluble crude lysate was 
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separated from insoluble crude lysate by centrifugation at 13,000 rpm for 30 min at 4°C. 
Supernatant fluid (50 µl of soluble crude lysate) and cell pellet (50 µl of insoluble crude 
lysate) was saved for SDS-PAGE analysis. 
(ii) Purification via affinity chromatography. The recombinant 1 2a-HSDH was 
purified using Strep-Tactin® resin according to the manufacturing protocol (IBA GmbH). 
Enzyme Characterization. (i) Kinetic analysis of recombinant 12a-HSDH. 
Enzyme reactions were determined by observing the oxidation and reduction activities in 
the presence of nicotinamide adenine dinucleotide phosphate (NADP+) and the reduced 
form (NADPH) at 340 nm for l .5 min; reactions were observed with the recombinant 
enzyme 1 2a-HSDH from C. scindens ATCC 35704 and various bile acid substrates. Data 
was analyzed using Michaelis-Menten equation and a nonlinear regression method using 
enzyme kinetics methods in GraphPad Prism (GraphPad software, La Jolla, CA, USA). 
1 2a-HSDH activities were also analyzed by (i) varying recombinant enzyme 
concentrations for the oxidative direction and reductive directions; (ii) varying substrate 
concentrations for DCA and 1 2-oxo-LCA; and varying NADP+ (DCA) and NADPH ( 1 2-
oxoLCA). 
(ii) The pH optimization of recombinant 12a-HSDH. Optimal pH was determined 
by varying the pH level of the assay in order to reach the optima enzyme activity in both 
the oxidative direction (DCA/NADP+) and the reductive direction ( 12-oxoLCA/NADPH). 
(iii) Sodium Dodecyl Sulfate Polyacrylamide Gel Electrophoresis (SDS-PAGE). 
The purity of the recombinant protein was determined by SOS-PAGE analysis. 2 µJ of the 
extracted protein was loaded into each compartment in the prepared gel, and the protein 
bands were visualized by Coomassie brilliant blue G-250 staining. Protein concentrations 
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were measured based on the portion extinction coefficient and molecular mass at the 
University of Illinois at Urbana-Champaign. 
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4. RESULTS 
Growth. C. scindens ATCC 35704, C. scindens VPI 1 2708, C. hiranonis DSM 1 3275, 
and C. hylemonae DSM 1 5053 were grown in BHI broth to provide the nutrients necessary 
for the organisms to reach optimum growth during this study. When methanolic solutions 
of bile acids were added to BHI broth (final concentrations were 0. 1  mM for bile acids and 
0.9% for methanol in culture medium after inoculation), growth levels and patterns were 
essentially unchanged by these organisms, indicating that at the concentrations tested 12-
oxoLCA did not appear to positively or negatively impact the growth profiles of these 
organisms (Figure 4-7). C. scindens yielded the greatest growth compared to C. hylemonae 
and C. hiranonis, respectively (Figure 4-7). All tested organisms reached a stationary 
phase in 24-h in absence of bile acids. However, C. hylemonae and C. hiranonis took 72-
h to reach the stationary phase, while C. scindens reached the maximum growth in 48-h in 
the presence of bile acids substrate. 
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Fig 4. Comparison of the growth of Clostridium scindens ATCC 35704 in brain 
heart infusion (BHI) broth and BHI broth supplemented with 0.1 mM bile acid. 
Values represent the means of duplicate tubes. Symbols: +, BHI alone; •, 
cholic acid; 0, deoxycholic acid; .6.., and 12-oxolithicholic acid. 
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Fig S. Comparison of the growth of Clostridium scindens VPI 1 1 2708 in brain 
heart infusion (BHI) broth and BHI broth supplemented with 0. 1 mM bile acid. 
Values represent the means of duplicate tubes. Symbols: +, BHI alone; •. 
cholic acid; 0, deoxycholic acid; !:::., and 12-oxolithicholic acid. 
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Fig 6. Comparison of the growth of Clostridium hiranonis DSM 1 3275 in brain 
heart infusion (BHI) broth and BHI broth supplemented with 0.1 mM bile acid. 
Values represent the means of duplicate tubes. Symbols: +, BHI alone; •,  cholic 
acid; 0, deoxycbolic acid; �. and 12-oxolithicholic acid. 
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Fig 7. Comparison of the growth of Clostridium hylemonae DSM 15053 in brain 
heart infusion (BHI) broth and BHI broth supplemented with 0. 1 mM bile acid. 
Values represent the means of duplicate tubes. Symbols: +, BHI alone; •. cholic 
acid; 0, deoxycholic acid; 6., and 12-oxolithicholic acid. 
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Conversion of 12-oxoLCA to DCA. C. scindens A TCC 35704, C. hiranonis DSM 
1 3275 and C. hylemonae DSM 15053 were all capable of converting 1 2-oxoLCA to DCA 
when grown in BHI broth supplemented with 100 µM 1 2-oxoLCA (Figure 8). It should 
be noted that 1 2-oxoLCA and DCA were never observed in BHI cultures in the absence of 
1 2-oxoLCA supplementation (data not shown). A potential reaction for the formation of 
DCA from 12-oxoLCA is shown in Figure 8 and represents a reduction which consumes 2 
reducing equivalents (2H) during this conversion 
As a novel investigation, it was important to validate that the conversion of 12-
oxoLCA to DCA was the result of enzymatic activity (abiotic activity) by the organisms 
being tested rather than by chemical/physical activity (abiotic activity). In this regard, 
when 1 2-oxoLCA was incubated anaerobically at 37°C in sterile BHI broth (without 
inoculation) for five consecutive days, TLC analysis did not show any detectable 
conversion of 1 2-oxoLCA to DCA or any other products (Figure 9-10). 1 2-oxoLCA 
dissolved in methanol during preparation of standards was not abiotically converted to 
DCA. In addition, spent culture fluids were also examined to confirm that 12-oxoLCA 
reduction to DCA was not the result of dead cells, cell debris, or metabolic end products 
from these organisms (Figure 1 1). As a result, in the absence of actively growing cells, 
12-oxoLCA was not reduced to DCA, indicating that the growth of these organisms 
(abiotic activity) was responsible for the observed reduction (Figure 10- 1 1  ). 
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Fig 8. Metabolism of 12-oxolithocholic acid ( 1 2-oxoLCA) by Clostridium scindens 
A TCC 35704, Clostridium hylemonae DSM 15053, and Clostridium hiranonis 
DSM 13275. Organisms were grown in brain heart infusion broth (BHI) 
supplemented with l 00 µM bile acids. Bile acids were extracted from cultures, 
dried, re-suspended in methanol, and spotted on a 20-cm x 20-cm, AL SIL G, 250 
µm thick, non-UV, TLC plate. Solvent system used to separate bile acids was ethyl 
acetate, cyclohexane, and glacial acetic acid in a ratio of 12: 12 :  I .  Lane: [ l ] ,  100 
µM of methanolic standard of deoxycholic acid (DCA); [2], 100 µM of methanolic 
standard of 1 2-oxoLCA; [3], C. scindens with 12-oxoLCA; [4], C. hylemonae with 
1 2-oxoLCA; and [5], C. hiranonis with 12-oxoLCA. 
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Fig 9. Chemical reaction for the conversion (reduction) of 1 2-oxolithocholic acid ( 12-
oxoLCA) to deoxycholic acid (DCA). 
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( 12-oxoLCA ) 
Fig 10. Potential impact of brain heart infusion broth (BHI) and methanol on stability 
of 12-oxolithocholic acid ( 1 2-oxoLCA). 12-oxoLCA ( 1 00  µM) was incubated in BHI 
broth for five days at 37°C. Bile acids were extracted, dried, re-suspended in methanol, 
and spotted on a 20-cm x 20-cm, AL SIL G, 250 µm thick, non-UV, TLC plate. Solvent 
system used to separate bile acids was ethyl acetate, cyclohexane, and glacial acetic 
acid in a ratio of 12: 12 :  l .  Lane: [ 1 ], I 00 µM of methanolic standard of cholic acid 
(CA); [2], 100 µM of methanolic standard of deoxycholic acid (DCA); [3], 100 µM of 
methanolic standard of 12-oxoLCA; and [4], 1 2-oxoLCA incubated for five days in 
sterile BHI. 
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Fig 11. Metabolism of 12-oxolithocholic acid ( 1 2-oxoLCA) and deoxycholic acid 
(DCA) by Clostridium scindens ATCC 35704. As indicated otherwise, organism was 
grown in brain heart infusion broth (BHI) supplemented with 100 µM bile acids. Bile 
acids were extracted from cultures, dried, re-suspended in methanol, and spotted on a 
20-cm x 20-cm, AL SIL G, 250 µm thick, non-UV, TLC plate. Solvent system used 
to separate bile acids was ethyl acetate, cyclohexane, and glacial acetic acid in a ratio 
of 12: 12:  1 .  Lanes: [ 1 ] ,  spent BHI broth culture incubated with 100 µM 1 2-oxoLCA; 
[2], 100 µM metbanolic standard of 1 2-oxo-LCA; [3], a methanolic standard mix 
containing 100 µM of 12-oxoLCA and 100 µM of DCA; [4], C. scindens with 12-
oxoLCA; and [5], C. scindens with DCA. 
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7a-dehydroxylatioo. C. scindens ATCC 35704 and C. hiranonis DSM 13275. 
actively dehydroxylated CA to DCA when CA was added to BHI broth. In contrast, C. 
hylemonae DSM 15053 showed a reduced capacity for generating DCA from CA (Figure 
12). However, activity levels were different (increased) when C. hylemonae DSM 1 5053 
cells were induced by sequential passages in BHI supplemented with CA followed by TLC 
analysis (Figure 13). 
Specificity of bile acid transformation. (i) mono-oxo bile acids. C. scindens VPI 
1 2708 was apparently unable to transform 1 2-oxoLCA to DCA (Figure 14; Table 5), 
however, C. scindens A TCC 35704, C. hiranonis DSM 13275, and C. hylemonae DSM 
1 5053 were clearly able to convert 1 2-oxoLCA to DCA by reducing the hydroxyl group at 
carbon atom position 12  to an oxo group (Figure 9 and 14). In contrast, only C. scindens 
ATCC and C. hiranonis DSM 13275 were able to transform 7-oxoDCA to DCA (Figure 
15- 16; Table 4), and C. scindens ATCC 35704 generated CA from 7-oxoDCA (Figure 1 5 ;  
Table 4). Furthermore, C. scindens ATCC 35704, were unable to metabolize either DCA 
(Figure 16; Table 4) or 3-oxoDCA during growth (Figure 17-19; Table 4-5). 
Unexpectedly, instead of generating DCA, C. scindens ATCC 35704 and C. hylemonae 
DSM 1 5053 transformed 1 2-oxoCDCA completely to 7-oxoDCA (Figure 18- 19;  Table 4-
5), while C. hiranonis DSM 13275 partially metabolized 1 2-oxoCDCA to 7-oxoDCA 
(Figure 20; Table 4). C. scindens A TCC 35704 and C. hylemonae DSM 15053 transformed 
3-oxoCA incompletely to CA, and some of the 3-oxoCA was observed as a non­
metabolized substrate (Figure 18-19; Table 4). Moreover, only C. hiranonis DSM 13275 
was able to generate DCA and CA from 3-oxoCA (Figure 20; Table 4- 5). 
(ii) Di- and tri-oxo bile acids. Di- and tri-oxo bile acids were also tested to determine the 
possible capability of these organisms to metabolize other oxo-derivatives. C. scindens 
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ATCC 35704 transformed the 7, 1 2-dioxoLCA partially to both DCA and CA (Figure 2 1 ;  
Table 4- 5). Yet, C. hylemonae DSM 15053 did not yield any DCA from the 7, 12-
dioxoLCA; instead, this organism removed the 7-oxo and 12-oxo groups from the substrate 
and reduced the 3-hydroxyl group to produce 3-oxoCA as a final end product (Figure 22; 
Table 4- 5). 3, 7, 1 2-oxoLCA was the only tri-oxo bile acid evaluated in the present study 
(Table 5), and this oxo-substrate was transformed to DCA only by C. hylemonae DSM 
1 5053 (Figure 23; Table 4). However, 7, 1 2-dioxoLCA was entirely transformed to DCA 
by C. hiranonis DSM 13275 (Figure 24; Table 4); Nevertheless, C. scindens ATCC 35704 
and C. hiranonis DSM 1 3275 generated CA by reducing hydroxyl groups at the 3, 7, and 
1 2  positions of tri-oxoLCA (Figure 24-25; Table 4). Adclitionally, C. scindens ATCC 
35704 and C. hiranonis DSM 1 3275 also metabolized tri-oxoLCA differently by reducing 
the hydroxyl groups at only the 7 and 12  positions and ending up with 3-oxoCA (Figure 
24; Table 4 ). The second di-oxo bile acid was tested in this study was 3, 12-oxoLCA 
(Table 5), and C. scindens ATCC 35704, C. hiranonis DSM 1 3275, and C. hylemonae 
DSM 1 5053 generated 3-oxoDCA from 3, 1 2-oxoLCA (Figure 26-28; Table 4). This 
biotransformation appears to occur when the 1 2-oxo group is reduced to a 1 2-hydroxyl 
group, yielding 3-oxoDCA. The specific reactions and enzymes used by C. scindens 
ATCC 35704, C. hiranonis DSM 13275, and C. hylemonae DSM 15053 to metabolize 
these different oxo-derivatives are presently unknown. Further studies will be required to 
resolve these reactions, including studies designed to reveal the conditions which might 
influence oxo-bile acid metabolism by these organisms (Table 4). 
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Fig 12. Metabolism of choJic acid (CA) and 1 2-oxolithocholic acid ( 12-oxoLCA) by 
Clostridium scindens ATCC 35704 and Clostridium hylemonae DSM 15053. 
Organisms were grown in brain heart infusion broth (BHI) supplemented with 100 
µM bile acids. Bile acids were extracted from cultures, dried, re-suspended in 
methanol, and spotted on a 20-cm x 20-cm, AL SIL G, 250 µm thick, non-UV, TLC 
plate. Solvent system used to separate bile acids was ethyl acetate, cyclohexane, and 
glacial acetic acid in a ratio of 12: 12: 1 .  Lanes: [ l ], methanol with C. scindens; [2], 
methanol with C. hylemonae; [3], CA with C. scindens; [4], CA with C. hylemonae; 
[5], 1 2-oxoLCA with C. scindens; and [6], 12-oxoLCA with C. hylemonae. 
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Fig 13. Metabolism of cholic acid (CA) by C/ostridium hylemonae DSM 15053. 
Organism was grown in brain heart infusion broth (BHI) supplemented with 100 
µM CA, bile acids were extracted from cultures, dried, re-suspended in methanol, 
and spotted on a 20-cm x 20-cm, AL SIL G, 250 µm thick, non-UV, TLC plate. 
Solvent system used to separate bile acids was ethyl acetate, cyclohexane, and 
glacial acetic acid in a ratio of 12: 12: 1 .  Lanes: [ 1 ] ,  50 µM methanolic standard CA; 
[2], standard deoxycholic acid (DCA); [3, 4], 1st passage of C. hylemonae with CA; 
[5, 6], 2nd passage of C. hylemonae with CA. 
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Table 4. Bile acids transformations by Clostridium scindens A TCC 35704, Clostridium 
hiranonis DSM 1 3275, and Clostridium hvlemonae DSM 1 5053. 
Bile acid Bile acids detected after growth (24-72 h) 
added to Rr value culture a 
CA 3 CA 7-oxoDCA 12- DCA 3-oxoDCA -oxo oxoCDCA 
CA 0.04 ± C. hyle d ND C ND ND C. sci c. hir 0.02 b C. hir 
0.21 ± C. sci C. sci 3-oxoCA 0.03 C. hyle C. hyle C. hir ND C. hir C. hir C. hir 
7-oxoDCA 0.14± C. sci ND C. hyle ND C. sci C. hir 0.03 C. hir C. hir 
0.27 ± C. sci 12-oxoCDCA 0.06 ND ND C. hyle C.hir ND ND C. hir 
0.38 ± C. sci DCA 0.14 ND ND ND ND C. hyle ND C. hir 
0.56 ± C. sci 3-oxoDCA 0. 1 1  ND ND ND ND ND C. hyle C. hir 
0.51 ± C. sci 12-oxoLCA 0.14 ND ND ND ND C. hyle ND C. hir 
3, 12-dioxo- 0.55 ± C. sci LCA o.01c ND ND ND ND ND C. hyle C. hir 
7, 12-dioxo- 0.22 ± C. sci LCA 0.02' C. sci C. hyle ND ND C. hir ND 
3,7,12-trioxo- 0.46 ± C. sci C. sci ND ND C. hyle ND LCA 0.03' C. hir C. hir 
4 1  
a Final concentration of bile acid added to BHI culture was 0.1 mM. 
bTLC solvent used to detect mono-oxobile acids: (cyclohexane, ethyl acetate, and glacial 
acetic acid; 12 :  12: 1) .  
c TLC solvent used to detect di and tri-oxobile acids; (toluene, 1- 4 dioxane, and glacial 
acetic acid; 70:20:2). 
d Detection limit of bile acid was determined at ::;; I 0 µM. 
e Not detected. 
Abbreviation: (CA), cholic acid; (3-oxoCA), 3-oxocholic acid; (7-oxoDCA), 7-
oxodeoxycholic acid; ( 12-oxoCDCA), 12-oxochenodeoxycbolic acid; (DCA), 
deoxycholic acid; 3-oxoDCA, 3-oxodeoxycholic acid; ( 1 2-oxoLCA), 12-oxolithocholic 
acid; (3, 1 2-dioxoLCA), 3, 12-dioxolithocbolic acid; (7, 12-dioxoLCA), 7, 12-
dioxolithocholic acid; (3, 7, 12-trioxoLCA), 3, 7, 12-trioxolithocholic acid. C. sci, 
Clostridium scindens ATCC 35704; C. hir, Clostridium hiranonis DSM 13275; and C. 
hyle, Clostridium hylemonae DSM 15053. 
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Fig 14. Metabolism of deoxycholic acid (DCA) and 1 2-oxolithocholic acid (12-
oxoLCA) by Clostridium scindens ATCC 35704, Clostridium hiranonis DSM 13275, 
and Clostridium scindens VPI 1 2708. Organism was grown in brain heart infusion 
broth (BHI) supplemented with 100 µM bile acids. Bile acids were extracted from 
cultures, dried, re-suspended in methanol, and spotted on a 20-cm x 20-cm, AL SIL G, 
250 µm thick, non-UV, TLC plate. Solvent system used to separate bile acids was ethyl 
acetate, cyclohexane, and glacial acetic acid in a ratio of I 2: 12:  I .  Lane: [ l ], C. scindens 
VPI with DCA; [2], C. scindens VPI with 1 2-oxoLCA; [3], C. hiranonis with DCA; 
[4], C. hiranonis with 12-oxoLCA; [5], 1 mM standard DCA; [6], 100 µM standard 12-
oxoLCA. 
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Table 5. Oxo bile acids structures. 
OH OH 
CA 12-oxoLCA 
H 
OH OH 
3-oxoCA 3-oxoDCA 
H 
OH OH 
7-oxoDCA 3,12-oxoDCA 
HO''" .  0 
H H 
OH OH 
1 2-oxoCDCA 7, 12-oxoCA 
HO'''' .. HO''''" H 
OH OH 
DCA 3, 7, 12-oxoCA 
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Structure of the bile acids in this study. (CA), cholic acid; (3-oxoCA), 3-oxocholic acid; 
(7-oxoDCA), 7-oxodeoxycholic acid; ( 12-oxoCDCA), 12-oxochenodeoxycholic acid; 
(DCA), deoxycholic acid; (3-oxoDCA), 3-oxodeoxycholic acid; ( 12-oxoLCA), 12-
oxolithocholic acid; (DCA), deoxycholic acid; ( 12-oxoCDCA), 12-oxochenodeoxycholic 
acid; (3, 12-dioxoLCA), 3, 12-dioxolithocholic acid; (7, 12-dioxoLCA), 7, 12-
dioxolitocholic acid; (3, 7, 1 2-trioxoLCA), 3, 7, 12-trioxolithocholic acid. 
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Fig 15. Metabolism of7-oxodeoxycholic acid (7-oxoDCA) by Clostridium sci11de11s 
ATCC 35704, Clostridiwn hiranonis DSM 1 3275, and Clostridium hylemonae 
DSM 15053. Organisms were grown in brain heart infusion broth (BHn 
supplemented with 100 µM 7-oxoDCA, bile acids were extracted from cultures 
sterile brain heart infusion broth (BHI), dried, re-suspended in methanol, and spotted 
on a 20-cm x 20-cm, AL SIL G, 250 µm thick, non-UY, TLC plate. Solvent system 
used to separate bile acids was ethyl acetate, cyclohexane, and glacial acetic acid in 
a ratio of 12: 12:  1 .  Lanes: [ 1 ], standard bi le acid mix containing: [A], (3-oxoDCA); 
[B], 12-oxolithocholic acid( 12-oxoLCA); [C], deoxycholic acid(DCA); [D], 12-
oxochenodeoxycholic acid ( 12-oxoCDCA); [E], 3-oxocholic acid (3-oxoCA); and 
[F], 7-oxodeoxycholic acid (7-oxoDCA); [2, 3], C. scindens; [4, 5], C. lziranonis; 
and [6, 7], C. hylemonae. 
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Fig 16. Metabolism of deoxycholic acid (DCA) by Clostridium scindens ATCC 
35704, Clostridium hiranonis DSM 13275, and Clostridium hylemonae DSM 1 5053. 
Organisms were grown in  brain heart infusion broth (BHI) supplemented with I 00 
µM DCA, bile acids were extracted from cultures, dried, re-suspended in methanol, 
and spotted on a 20-cm x 20-cm, AL SIL G, 250 µm thick, non-UV, TLC plate. 
Solvent system used to separate bile acids was ethyl acetate, cyclohexane, and glacial 
acetic acid in a ratio of 1 2 : 1 2 : 1 .  Lanes: [ l ] , standard bile acid mix containing : [A], 
3-oxodeoxycholic acid (3-oxoDCA); [B], DCA; [CJ, 1 2-oxochenodeoxycholic acid 
( 1 2-oxoCDCA); [DJ, 3-oxocholic acid (3-oxoCA); and [E], 7-oxodeoxycholic acid 
(7-oxoDCA); [2, 3], C. scindens; [4, 5], C. hiranonis; and , [6, 7], C. hylemonae. 
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Fig 17. Metabolism of 3-oxodeoxycholic acid (3-oxoDCA) by Clostridium scindens 
ATCC 35704, Clostridium hiranonis DSM 13275, and Clostridium hylernonae DSM 
1 5053. Organisms were grown in brain heart infusion broth (BHn supplemented with 
100 µM 3-oxoDCA, bile acids were extracted from cultures, dried, re-suspended in 
methanol, and spotted on a 20-cm x 20-cm, AL SIL G, 250 µm thick, non-UV, TLC 
plate. Solvent system used to separate bile acids was ethyl acetate, cyclohexane, and 
glacial acetic acid in a ratio of 12: 1 2: 1 .  Lanes: [ l ], standard bile acid mix containing 
(A], 3-oxoDCA; [B], 12-oxolithocholic acid ( 12-oxo-LCA); [C], deoxycholic acid 
(DCA); [D], 12-oxochenodeoxycholic acid ( 1 2-oxoCDCA); [E], 3-oxocholic acid (3-
oxoCA); [F], 7-oxodeoxycholic acid (7-oxoDCA); (2, 3), C. scindens; [4, 5), C. 
hiranonis; and (6, 7), C. hylemonae. 
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Fig 18. Metabolism of bile acids derivatives by C/ostridium scindens ATCC 35704. 
Organism was grown in brain heart infusion broth (BHI) supplemented with 100 µM 
bile acids, bile acids were extracted from cultures, dried, re-suspended in methanol, and 
spotted on a 20-cm x 20-cm, AL SIL G, 250 µm thick, non-UV, TLC plate. Solvent 
system used to separate bile acids was ethyl acetate, cyclohexane, and glacial acetic acid 
in a ratio of 12: 12: l .  Lanes: [ l ] ,  standard bile acid mix containing: [A], 3-oxoDCA; 
[B], 1 2-oxolithocholic acid (1 2-oxoLCA); [C], deoxycbolic acid (DCA); [D], 12-
oxochenodeoxycholic acid ( 1 2-oxoCDCA); [E], 3-oxocholic acid (3-oxoCA); [F], and 
7-oxodeoxycholic acid (7-oxoDCA); [G]; cholic acid; [2], C. scindens with CA; [3], C. 
scindens with 7-oxo-DCA; [4], C. scindens with 3-ox-CA; [5], C. scindens with 12-
oxoCDCA; [6], C. scindens with DCA; [7], C. scindens with 12-oxo-LCA; [8], C. 
scindens with 3-oxoDCA. 
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Fig 19. Metabolism of bile acids derivatives by Clostridium hylemonae DSM 15053. 
Organisms were grown in brain heart infusion broth (BHI) supplemented with 100 
µM bile acids, bile acids were extracted from cultures, dried, re-suspended in 
methanol, and spotted on a 20-cm x 20-cm, AL SIL G, 250 µm thick, non-UV, TLC 
plate. Solvent system used to separate bile acids was ethyl acetate, cyclohexane, and 
glacial acetic acid in a ratio of 12: 12:  1 .  Lanes: [ l ], standard bile acid mix containing 
[A], 3-oxoDCA; [B], 12-oxolithocholic acid( l 2-oxoLCA); [C], deoxycholic acid 
(DCA); [D], 12-oxochenodeoxycholic acid ( 1 2-oxo-CDCA); [E], 3-oxocholic acid 
(3-oxoCA); [F], 7-oxodeoxycholic acid (7-oxoDCA); [G], cholic acid(CA); [2], C. 
lzylemonae with CA; [3], C. hylemonae with 7-oxoDCA; [4], C. hylemonae with 3-
oxoCA; [5], C. hylemonae with 12-oxoCDCA; [6], C. hylemonae with DCA; [7], C. 
hylemonae with 12-oxoLCA; (8), C. hylemonae with 3-oxoDCA. 
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Fig 20. Metabolism of bile acids derivatives by Clostridium hiranonis DSM 1 3275. 
Organism was grown in brain heart infusion broth (BHI), bile acids were extracted 
from cultures, dried, re-suspended in methanol, and spotted on a 20-cm x 20-cm, 
AL SIL G, 250 µm thick, non-UV, TLC plate. Solvent system used to separate bile 
acids was ethyl acetate, cyclohexane, and glacial acetic acid in a ratio of 12:  12: I. 
Lanes: 1 ,  100 µM standard bile acid mix containing: [A], 3-oxodeoxycholic acid (3-
oxo-DCA); [B], 1 2-oxolithocholic acid ( 1 2-oxoLCA) [C]; deoxycholic acid (DCA) 
[D], 12-oxochenodeoxycholic acid ( 12-oxoCDCA); [E], 3-oxocholic acid (3-
oxoCA); and [F], 7-oxodeoxycholic acid (7-oxoDCA); [G], cholic acid(CA); 2, C. 
hiranonis with CA; 3, C. hiranonis with 7-oxoDCA; 4, C. hiranonis with 3-oxoCA; 
5, C. hiranonis with 12oxoCDCA; 6, C. hiranonis with DCA; 7, C. hiranonis with 
1 2-oxoLCA; 8, C. hiranonis with 3-oxoDCA. 
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Fig 21. Metabolism of [3, 1 2-dioxolithocholic acid (3, 1 2-dioxoLCA); 7,  1 2-
dioxolitocholic acid (7, 1 2-dioxoLCA); 3, 7, 1 2-trioxolitbocholic acid (3, 7, 12-
trioxoLCA)] by Clostridium scindens A TCC 35704. Organism was grown in brain 
heart infusion broth (BHI), supplemented with 100 µM bile acids, and bile acids were 
extracted from cultures, dried, re-suspended in methanol, and spotted on a 20-cm x 20-
cm, AL SIL G, 250 µm thick, non-UV, TLC plate. Solvent system used to separate 
bile acids was ethyl acetate, cycJohexane, and glacial acetic acid in a ratio of 12: 1 2: 1 .  
Lanes: [ l ], I mM standard bile acid mix; (2), 100 µM standard bile acid mix containing 
: [A], 3-oxodeoxycholic acid(3-oxoDCA); [B], 12-oxolithocholic acid ( 1 2-oxoLCA); 
[C], deoxycholic acid (DCA); [D], 1 2-oxochenodeoxycholic acid ( 1 2-oxoCDCA); [E], 
3-oxocho lic acid (3-oxoCA); [F], 7-oxodeoxycholic acid (7-oxoDCA); [G], cholic 
acid(CA); [3, 4], C. scindens with 3, 12-dioxoLCA); (5, 6], C. scindens with 7, 1 2-
dioxoLCA; (7, 8], C. scindens with 3, 7, 1 2-trioxoLCA). 
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Fig 22. Metabolism of (3, 1 2-dioxolithocholic acid (3, 1 2-dioxoLCA); 7, 12-
dioxolitocholic acid (7, 12-dioxoLCA); 3,  7, 1 2-trioxolithocholic acid (3, 7, 12-
lrioxoLCA)] by Clostridium hylemonae DSM 1 5053. Organism was grown in brain 
heart infusion broth (BHI) supplemented with l 00 µM bile acids, bile acids were 
extracted from cultures, dried, re-suspended in methanol, and spotted on a 20-cm x 
20-cm, AL SIL G, 250 µm thick, non-UV, TLC plate. Solvent system used to separate 
bile acids was ethyl acetate, cyclohexane, and glacial acetic acid in a ratio of 12:  12:  1 .  
Lanes: [ I ] , I mM standard bile acid mix; [2], 100 µM standard bile acid mix 
containing: [A], 3-oxodeoxycholic acid(3-oxoDCA); [B), 1 2-oxolithocholic acid ( 1 2-
oxoLCA); [C], deoxycholic acid (DCA); [D], 12-oxochenodeoxyholic acid ( 12-
oxoCDCA); [E], 3-oxcholic acid (3-oxoCA); [F], 7-oxodeoxycholic acid (7-
oxoDCA); [G], cholic acid(CA); [3, 4], C. hylemonae with 3, 12-dioxoLCA; [5, 6], C. 
hylemonae with 7, 1 2-dioxoLCA; (7, 8], C. hylemonae with 3, 7, 12-trioxoLCA. 
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Fig 23. Metabolism of [3, 12-dioxolithocholic acid (3, 12-dioxoLCA); 7, 12-
dioxolitocholic acid (7, 1 2-dioxoLCA); 3, 7, 12-trioxolithocholic acid (3, 7, I 2-
trioxoLCA)] by Clostridium hylemonae DSM 1 5053. Organism was grown in brain 
heart infusion broth (BHI) supplemented with 100 µM bile acids, bile acids were 
extracted from cultures, dried, re-suspended in methanol, and spotted on a 20-cm x 
20-cm, AL SIL G, 250 µm thick, non-UV, TLC plate. Solvent system used to 
separate bile acids was ethyl acetate, cyclohexane, and glacial acetic acid in a ratio 
of 12 : 12: 1 .  Lanes: [ l ], 1 mM standard bile acid mix; [2], 1 00  µM standard bile acid 
mix containing: [A], 3-oxodeoxycholic acid(3-oxoDCA); [B], 12-oxolithocholic acid 
( 12-oxoLCA); [C], deoxycholic acid (DCA); [D], 12-oxochenodeoxycholic acid ( 1 2-
oxoCDCA); [E], 3-oxocholic acid (3-oxoCA); [F], 7-oxodeoxycholic acid (7-
oxoDCA); [G], cholic acid(CA); [3, 4], C. hylemonae with 3, 12-dioxoLCA); [5, 6], 
C. hylemonae with 7, 12-dioxoLCA); [7, 8], C. hy/emonae with 3, 7, 12-trioxoLCA). 
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Fig 24. Metabolism of [3, 1 2-dioxolithocholic acid (3, 1 2-dioxoLCA); 7, 12-
dioxolithocholic acid (7, 1 2-trioxoLCA); 3,  7, 1 2-trioxolithocholic acid (3, 7,  12-
trioxoLCA)] by Clostridium hiranonis DSM 13275. Organism was grown in brain 
heart infusion broth (BHI) supplemented with 100 µM of 3, 12-dioxoLCA; 7, 12-
dioxoLCA; or 3, 7, 12-trioxoLCA, bile acids were extracted from cultures, dried, re­
suspended in methanol, and spotted on a 20-cm x 20-cm, AL SIL G, 250 µm thick, 
non-UV, TLC plate. Solvent system used to separate bile acids was ethyl acetate, 
cyclohexane, and glacial acetic acid in a ratio of 12 :  12: 1 .  Lanes: [ 1 ], 1 mM standard 
bile acid mix , [2], 100 µM standard bile acid mix containing : [A], 3-oxodeoxycholic 
acid(3-oxoDCA); [B], 1 2-oxolithocholic acid ( 1 2-oxoLCA); [C], deoxycholic acid 
(DCA); [D], 1 2-oxochenodeoxycholic acid ( 1 2-oxoCDCA); [E], 3-oxocholic acid (3-
oxoCA); [F], 7-oxodeoxycholic acid (7-oxoDCA); [G], cholic acid(CA); [3, 4], C. 
hiranonis with 3, 1 2-dioxoLCA; [5, 6], C. hiranonis with 7, 1 2-dioxoLCA; [7, 8], C. 
hiranonis with 3, 7, 1 2-trioxoLCA. 
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Fig 25. Metabolism of (3, 12-dioxolithocholic acid (3, 12-dioxoLCA); 7, 12-
dioxolithocholic acid (7, 12-trioxoLCA); 3, 7, 12-trioxolithocholic acid (3, 7, 12-
trioxoLCA)] by Clostridium scindens ATCC 35704. Organism was grown in brain 
heart infusion broth (BHI) supplemented with 100 µM bile acids. Bile acids were 
extracted from cultures, dried, re-suspended in methanol, and spotted on a 20-cm x 20-
cm, AL SIL G, 250 µm thick, non-UV, TLC plate. Solvent system used to separate 
bile acids was ethyl acetate, cyclohexane, and glacial acetic acid in a ratio of 12: 12: l .  
Lanes: [ l ] ,  1 mM standard bile acid mix , (2), I 00 µM standard bile acid mix 
containing : [A], 3-oxodeoxycholic acid(3-oxoDCA); [B], 12-oxolithocholic acid ( 12-
oxoLCA); [C], deoxycholic acid (DCA); [D], 12-oxochenodeoxycholic acid ( 1 2-
oxoCDCA); [E], 3-oxocholic acid (3-oxoCA); [F], 7-oxodeoxycholic acid (7-
oxoDCA); [G], cholic acid(CA); [3, 4], C. scindens with 3, 12-dioxo-LCA; [5, 6), C. 
scindens with 7, 12-dioxoLCA; [7, 8), C. scindens with 3, 7, 12-trioxoLCA. 
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Fig 26. Metabolism of [3, 12-dioxolithocholic acid (3, 1 2-dioxoLCA); 7, 12-
dioxolithocholic acid (7, 1 2-trioxoLCA); 3, 7, 1 2-trioxolithocholic acid (3, 7, 12-
trioxoLCA)] by Clostridium scindens A TCC 35704. Organism was grown in brain 
heart infusion broth (BHI) supplemented with 1 00  µM bile acids. Bile acids were 
extracted from cultures, dried, re-suspended in methanol, and spotted on a 20-cm x 20-
cm, AL SIL G, 250 µm thick, non-UV, TLC plate. Solvent system used to separate 
bi le acids was ethyl acetate, cycJohexane, and glacial acetic acid in a ratio of I 2: 12:  1 .  
Lanes: [ l ] ,  l mM standard bile acid mix , [2], 100 µM standard bile acid mix 
containing : [A], 3-oxodeoxycholic acid(3-oxoDCA); [B], 12-oxolithocholic acid ( 12-
oxoLCA); [C], deoxycholic acid (DCA); [D], 1 2-oxochenodeoxycholic acid ( 1 2-
oxoCDCA); [E], 3-oxocholic acid (3-oxoCA); [F], 7-oxodeoxycholic acid (7-
oxoDCA); [G], cholic acid(CA); [3, 4], C. scindens with 3, 1 2-dioxoLCA; [5, 6], C. 
scindens with 7, 12-dioxoLCA; [7, 8], C. scindens with 3, 7, 12-trioxoLCA. 
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Fig 27. Metabolism of [3, 12-ctioxolithocholic acid (3, 12-dioxoLCA); 7, 12-
dioxolitocholic acid (7, 12-dioxoLCA); 3, 7, 1 2-trioxolithocholic acid (3, 7, 12-
trioxoLCA)] by Clostridium hiranonis DSM 13275. Organism was grown in brain 
heart infusion broth (BHI), supplemented with 100 µM bile acids. Bile acids were 
extracted from cultures.._dried, re-suspended in methanol, and spotted on a 20-cm x 
20-cm, AL SIL G, 250 µm thick, non-UV, TLC plate. Solvent system used to separate 
bile acids was ethyl acetate, cyclohexane, and glacial acetic acid in a ratio of 12:  12: 1 .  
Lanes: [ 1 ], I mM standard bile acid mix; [2], 100 µM standard bile acid mix 
containing: [A], 3-oxodeoxycholic acid(3-oxoDCA); [B], 1 2-oxolithocholic acid ( 12-
oxoLCA); [C], deoxycholic acid (DCA); [D], 1 2-oxochenodeoxycholic acid ( 1 2-
oxoCDCA); [E], 3-oxocholic acid (3-oxoCA); [F], 7-oxodeoxycholic acid (7-
oxoDCA); [G], cholic acid(CA); [3, 4], C hiranonis with 3, 12-dioxoLCA; [5, 6], C. 
hiranonis with 7, 1 2-dioxoLCA; [7, 8], C. hiranonis with 3, 7, 12-trioxoLCA. 
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Fig 28. Metabolism of [3, 1 2-dioxolithocholic acid (3, 12-dioxoLCA); 7, 1 2-
dioxolitocholic acid (7, 12-dioxoLCA); 3, 7, 1 2-trioxolithocholic acid (3, 7, 12-
trioxoLCA)] by Clostridium hylemonae DSM 1 5053. Organism was grown in brain 
heart infusion broth (BHD supplemented with 100 µM bile acids. Bile acids were 
extracted from cultures, dried, re-suspended in methanol, and spotted on a 20-cm x 
20-cm, AL SIL G, 250 µm thick, non-UV, TLC plate. Solvent system used to separate 
bile acids was ethyl acetate, cyclohexane, and glacial acetic acid in a ratio of 12:  12:  1 .  
Lanes: [ 1 ] ,  1 mM standard bile acid mix; [2], 1 00  µM standard bile acid mix 
containing: [A], 3-oxodeoxycholic acid(3-oxoDCA); [B], 12-oxolithocholic acid ( 1 2-
oxoLCA); [C], deoxycholic acid (DCA); [D], 1 2-oxochenodeoxycholic acid ( 12-
oxoCDCA); [E], 3-oxocholic acid (3-oxoCA); [F], 7-oxodeoxycholic acid (7-
oxoDCA); [G], cholic acid(CA); [3, 4), C. hylemonae with 3, 1 2-dioxoLCA); [5, 6], 
C. hylemonae with 7, 12-dioxoLCA); [7, 8), C. hylemonae with 3, 7, 12-trioxoLCA). 
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Metabolism of bile acid combinations. (i) CA and DCA. A combination of CA and 
DCA, each at a final concentration of 0. 1 mM, were added to BHI broth to evaluate the 
ability of these organisms (i) to dehydroxylate CA in the presence of DCA and (ii) to 
produce any possible novel products from CA or DCA metabolism. C. scindens ATCC 
35704, C. scindens VPI 12708, C. hiranonis DSM 1 3275, and C. hylemonae DSM 1 5053 
were all incapable of metabolizing DCA (Figure 16). Thus, it was difficult to determine 
whether the combination of CA and DCA suppressed the conversion of CA to DCA to any 
notable degree given the qualitative nature of TLC analysis. However, C. scindens ATCC 
35704 and C. hiranonis DSM 13275 cultures did reveal a faint spot of CA upon TLC 
analysis which indicated that both organisms transformed CA partially to DCA (Figure 
29). C. hiranonis DSM 13275 formed other unknown products beside CA and DCA, and 
it was difficult to identify the unknown products via TLC only (Figure 29). C. hylemonae 
DSM 1 5053 cultures yielded a darker, more intense CA spot on the TLC plate while the 
spot intensity for DCA was similar to the DCA standard, which also indicated the weak 
activity of C. hylemonae DSM 1 5053 to generate DCA from CA (Figure 29). 
Considerably, C. scindens VPI 1 2708 appeared to convert most, if not all, of the CA to 
make DCA without the generation of any unknown product(s) (Figure 29). However, C. 
scindens VPI 12708 was eliminated from further experiments in the present study due to 
its inability to transform 12-oxoLCA to DCA (Figure 9). 
(ii) CA and 12-oxoLCA. Another combination of bile acid consisting of CA and 12-
oxoLCA was applied in this study to examine another aspect of dehydroxylation/reduction 
by determining if a mixture of bile acids was metabolized differently than when a single 
bile acid was added to BHI broth. To examine this possibility, two culture conditions were 
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tested. First, to evaluate if CA induction impacted the bioconversion of CAf12-oxoLCA 
mixture, cells were initially cultured with CA ( 151 passage) and then transferred to BHI 
broth supplemented with both CA and 12-oxoLCA (2"d passage). The second culture 
condition examined was the bioconversion of CN12-oxoLCA mixture directly without 
prior induction of cells with CA. Under both conditions, C. scindens ATCC 35704 
revealed the same products, DCA, CA, 3-oxoDCA, and an unknown product (Figure 30). 
This unknown product appeared to be similar to 3-oxoCA, 7-oxoDCA, or 12-oxoLCA 
(Figure 30). 
(iii) CA and 12-oxoCDCA. A combination of CA and 12-oxoCDCA was also 
examined using the same experimental approach as described above for the CAfl2-
oxoLCA mix. In these experiments, C. scindens produced DCA and 7-oxoDCA under 
both culture conditions (induced/non-induced cells) (Figure 3 1) .  An undetermined product 
similar to 3-oxoDCA was also formed under both culture conditions (Figure 3 1). 
For C. hiranonis, cells actively formed DCA in BHI supplemented with the CAf 12-
oxoCDCA mix (Figure 32). The DCA was apparently produced from CA dehydroxylation 
since 1 2-oxoCDCA was metabolized very little, if at all, by either induced or non-induced 
cells. 3-oxoCA, and 3-oxoDCA were identified as additfonal products under both culture 
conditions (Figure 32). 
Interestingly, C. hylemonae DSM 15053 completely consumed 12-oxoCDCA under 
both culture conditions (induced/non-induced cells) (Figure 33). Based on the results 
shown in Table 4 for individual bile acids, C. hylemonae DSM 1 5053 has the capacity to 
convert 12-oxoCDCA solely to 7-oxoDCA (Table 4). 7-oxoDCA did not seem to be 
metabolized further by C. hylemonae DSM 15053 (Table 4). With non-induced cells, CA 
was not appreciably dehydroxylated to DCA (Figure 33; Table 4). In sharp contrast, 
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induced cells of C. hylemonae DSM 1 5053 appeared to have more metabolic capabilities 
than noninduced cells. For example, induced cells were able to readily produce DCA, 
apparently from CA, although it is also possible that some of the DCA was derived from 
7-oxoDCA (e.g., requiring oxo-group reduction and dehydroxylation at the C-7 position) 
or 1 2-oxoCDCA (e.g., requiring dehydroxylation at the C-7 position and oxo-group 
reduction at the C-12 position). In this regard, induced cells, unlike non-induced cells, 
were able to produce 1 2-oxoLCA from the CN12-oxoCDCA mixture, with 12-oxoCDCA 
a likely candidate. However, the ultimate bile acid source(s) for 1 2-oxoLCA formation 
remain to be determined as well as the reason for 1 2-oxoLCA accumulation when 12-
oxoLCA reduction to DCA is possible (Figure 33). Nonetheless, these findings seem to 
suggest that for some bile acid-metabolizing bacteria hydroxyl-group removal from oxo­
bile acids, like non-oxo-bile acids, is an inducible metabolic feature. Such potential 
metabolic potentials will require further studies in C. hylemonae DSM 15053 and other 
bile acid-dehydroxylating bacteria. 
Potential regulatory substrates for 12-oxoLCA reduction to DCA. 
Hypothetically, it was important to examine the impact of potential electron acceptors 
thiosulfate (S2032-) and nitrate (NQ3-) or potential electron donors such as hydrogen gas 
(H2), pyruvic acid (C3H4Q3), and formate (HC02-) on the conversion of 1 2-oxoLCA to 
DCA. It should be noted that (H2), pyruvic acid (C3H4Q3), and formate (HC02-) are also 
end products formed during glucose fermentation by C. scindens ATCC 35704 (40, 41)  
Overall, the presence of  these potential electron acceptors or electron donors did not appear 
to impact the conversion of 1 2-oxoLCA to DCA by C. scindens A TCC 35704 during 
growth (Figure 34). 
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DCA 
CA 
Fig 29. Metabolism of mix bile acid containing cholic acid (CA) and deoxycholic acid 
(DCA) by Clostridium hylemonae DSM 15053, Clostridium scindens VPI 1 2708, 
Clostridium paraputrificum, Clostridium hiranonis DSM 1 3275, and Clostridium 
scindens ATCC 35704. Organism were grown in brain heart infusion broth (BHI), 
supplemented with 100 µM bile acids. Bile acids were extracted from cultures, dried, 
re-suspended in methanol, and spotted on a 20-cm x 20-cm, AL SIL G, 250 µm thick, 
non-UV, TLC plate. Solvent system used to separate bile acids was ethyl acetate, 
cyclohexane, and glacial acetic acid in a ratio of 12:  12: 1 .  Lane: [ l ] ,  100 µM of standard 
CA; 2, 100 µM of standard DCA; 3, C. hylernonae DSM 15053 with CA/DCA; 4, C. 
scindens VPI 12708 with CA/DCA; 5, C. paraputrificum with CA/DCA; 6, C. 
hiranonis DSM 13275 with CA/DCA; and 7, C. scindens ATCC 35704 with CA/DCA. 
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Fig 30. Metabolism of mix bile acids containing cholic acid (CA) and 12-
oxolithocholic acid (1 2-oxoLCA) by Clostridium scindens ATCC 35704. Organjsm 
was grown in brain heart infusion (BHI) broth supplemented with 100 µM bile acids 
Bile acids were extracted from cultures, dried, re-suspended in methanol, and spotted 
on a 20-cm x 20-cm, AL SIL G, 250 µm thick, non-UV, TLC plate. Solvent system 
used to separate bile acids was ethyl acetate, cyclohexane, and glacial acetic acid; 
12: 12:  1. Lanes: [ l ] ,  standard CA; [2], standard deoxycholic acid (DCA); [3], standard 
12-oxoLCA; [4], C. scindens with 1 2-oxoLCA; [5, 6], C. scindens induced with CA 
for overnight prior to inculcated with 1 2-oxoLCA; [7, 8], C. scindens with combination 
of (CA/ 1 2-oxoCDCA) at final concentration of 100 µM; [A], 3-oxolithocholic acid (3-
oxoDCA); [B], deoxycholic acid (DCA) ; [C] cholic acid (CA). 
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Fig 31. Metabolism of a combination of cholic acid (CA) and 12-
oxochenodeoxycholic acid ( 12-oxoCDCA) by Clostridium scindens ATCC 35704. 
Organism was grown in brain heart infusion (BHI) broth supplemented with 100 µM 
bile acids. Bile acids were extracted from cultures, dried, re-suspended in methanol, 
and spotted on a 20-cm x 20-cm, AL SIL G, 250 µm thick, non-UV, TLC plate. 
Solvent system used to separate bile acids was ethyl acetate, cyclohexane, and glacial 
acetic acid in a ratio of 12: 12: 1 .  Lanes: [ l ] ,  50 µM standard CA; [2], standard 
deox ycholic acid (DCA); [3], standard 12-oxoCDCA; [ 4, 5], J51 passage of C. scindens 
with CA/ 12-oxoCDCA; and [ 6, 7), 2nd passage of C. scindens with CA/ 12-oxoCDCA. 
65 
3-oxoDCA 
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Fig 32. Metabolism of a combination of cholic acid (CA) and 12- oxochenodeoxycholic 
acid ( 1 2-oxoCDCA) by ClostrMium hiranonis DSM 13275. Organism was grown in 
brain heart infusion broth (BHI), supplemented with 100 µM bile acids. Bile acids were 
extracted from cultures, dried, re-suspended in methanol, and spotted on a 20-cm x 20-
cm, AL SIL G, 250 µm thick, non-UV, TLC plate. Solvent system used to separate bile 
acids was ethyl acetate, cyclohexane, and glacial acetic acid in a ratio of 12: 12: 1 .  Lanes: 
( 1 ) ,  50 µM standard CA; [2], standard deoxycholic acid (DCA); [3], standard 12-
oxoCDCA; [4, 5], 1 s1passage of C. hiranonis with CA/1 2-oxoCDCA; (6, 7], 2"d passage 
of hira11onis with CA/1 2-oxoCDCA. 
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Fig 33. Metabolism of a combination of cholic acid (CA) and 12-
oxochenodeoxycholic acid ( 12-oxoCDCA) by Clostridiurn hylemonae DSM 15053. 
Organism was grown in brain heart infusion broth (BHI), supplemented with 100 µM 
bile acids. Bile acids were extracted from cultures, dried, re-suspended in methanol, 
and spotted on a 20-cm x 20-cm, AL SIL G, 250 µm thick, non-UV, TLC plate. 
Solvent system used to separate bile acids was ethyl acetate, cyclohexane, and glacial 
acetic acid in a ratio of 12 :  12: l .  Lanes: [ l ] ,  50µM standard CA; [2], standard 
deoxycholic acid (DCA); [3], standard 1 2-oxoCDCA; [4,5], ! 51 passage of C. 
hylemonae with CA/1 2-oxoCDCA; and (6,7], 2"d passage of hylemonae with CA/12-
oxoCDCA. 
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Fig 34. Metabolism of 12-oxolithocholic acid ( 1 2-oxoLCA) by Clostridium scindens 
ATCC 35704 in the presence of potential regulatory substrates. Organism was grown 
in brain heart infusion broth (BHI), each substrate ( 10  mM final concentration) was 
added separately to each culture supplemented with 100 µM 1 2-oxoLCA, and bile 
acids were extracted from cultures, dried, re-suspended in methanol, and spotted on a 
20-cm x 20-cm, AL SIL G, 250 µm thick, non-UV, TLC plate. Solvent system used 
to separate bile acids was ethyl acetate, cyclohexane, and glacial acetic acid; 12 :  1 2: 1 .  
Lanes: [ l ]  standard 12-oxolithocholic acid ( 12-oxoLCA); [2], standard deoxycholic 
acid (DCA); [3], C. scindens with thiosulfate (S203); [4], C. scindens with nitrate (N01· 
); [5], C. scindens with pyruvic acid (C:iH.i03); [6], C. scindens with hydrogen gas (H2); 
and [7], C. scindens with formate (HC02-). 
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Detection limit of bile acids. It was extremely important to determine the lowest 
detectable concentration of each bile acid used in this study. Knowing the minimal 
detectable amount allows better identification of products (fewer false negatives) and 
unspecified products (fewer false positives). Different concentrations of bile acids were 
added to BHI broth, extracted, and then analyzed by TLC using different solvent systems 
depending on the type of bile acid (e.g., mono; di; and tri) added to the medium. 
Consequently, the lowest amount of each bile acid was determined to be :5 10 µM in BHI 
broth (Figure 35-36). These results indicated that most, if not all, possible products from 
each bile acid transformation would be identifiable using the TLC method employed in this 
study. Despite the fact that some products were hard to identify without examining the 
corresponding standard on the same TLC plate, the low detection limit provided a high 
degree of confidence that the bile acid substrates and transformation products from bile 
acids would be measurable in BHI cultures used in this study (Figure 35-36). 
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Fig 35. TLC analysis of (I 0 µM) mono-bile acid standards in methanol. Bile acids 
were extracted from sterile brain heart infusion (BHI) broth supplemented with 10 µM 
bile acids, bile acids were extracted from BHI medium, dried, re-suspended in 
methanol, and spotted on a 20-cm x 20-cm, AL SIL G, 250 µm thick, non-UV, TLC 
plate. Solvent system used to separate bile acids was ethyl acetate, cyclohexane, and 
glacial acetic acid in a ratio of 1 2: 1 2 : 1 .  Lanes: [ 1 ] ,  cholic acid (CA); [2]. 7-
oxodeoxycholic acid (7-oxoDCA); [3], 3-oxocholic acid (3-oxoCA); [4], 12-
oxochenodeoxycholic acid ( 12-oxo-CDCA); [5], deoxycholic acid (DCA); [6], 12-
oxolithocholic acid ( 1 2-oxoLCA); [7], 3-oxodeoxycholic acid (3-oxoDCA). 
70 
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3,7,1 2-trioxoLCA 
Fig 36. TLC analysis of ( 1 0  µM) di and tri bile acids standards in methanol. Bile acids 
were extracted from sterile brain heart infusion (BHI) broth supplemented with 10 µM 
of bile acids, bile acids were extracted from BHI medium, dried, re-suspended in 
methanol, and spotted on a 20-cm x 20-cm, AL SIL G, 250 µm thick, non-UV, TLC 
plate. Solvent system used to separate bile acids was toluene, 1-4 dioxane, and glacial 
acetic acid in a ratio of 70:20:2. Lane [ 1  ] ,  7, 1 2-dioxolitocholic acid (7, 1 2-dioxoLCA); 
(2], 3, 7, 12-trioxolithocholic acid (3, 7, 12-trioxoLCA); [3], 3, 12-dioxolithocholic 
acid (3, 12-dioxoLCA). 
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Gene cloning and expression. (i) DNA amplification. Genomic DNA from C. 
scindens ATCC 35704 was provided by University of Illinois at Urbana-Champaign UIUC 
to amplify the putative 1 2a.-HSDH gene from C. scindens ATCC 35704. Cloning primers 
were used during the polymerase chain reaction (PCR) process in order to provide 
amplified l 2cx-HSDH copies for insertion into the cloning vector. It was important to 
assure the presence of the correct gene among the DNA amplification processes, and, to 
ensure that, gel electrophoresis was applied to detect DNA size and to confirm the 
correctness of the amplification, gene was successfully cloned and amplified for gene 
expression, recombinant 1 2a.-HSDH gene was visualized in a pure band and correct size 
compared to the digested vector (pET5 l ), with the proper restriction enzyme, and 
compared also with the undigested vector (Figure 37). 
(ii) Expression of recombinant protein. 1 2a.-HSDH gene was successfully inserted 
into the vector E. coli cells BL21 CodonPlus, transformed with pET5 l b  plasmid containing 
cloned gene of interest, 12a.-HSDH, into C. scindens. Inserted plasmid was followed by 
gel electrophoresis to identify the correct insertion of the plasmid (Figure 38). The selected 
plasmid from C. scindens was effectively sequenced at Carl R. Woese Institute for 
Genomic Biology at UIUC. Putative 1 2cx-HSDH gene sequence from C. scindens was 
aligned with the amino acid sequence of the l 2a.-HSDH gene from Clostridium spp. A TCC 
29733 (ERJ00208. l ) .  The nucleotide sequence of 12a.-HSDH from C. scindens confirmed 
that there were no point mutations before protein expression was done. (Table 6). 
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Fig 37. Gel electrophoresis image of the polymer chain reaction (PCR) with 
primers containing overhang for l 2cx-HSDH inserted into Clostridium scindens 
ATCC 35704. Lane: [ l ], I -kb DNA ladder; [2], 1 2cx-HSDH from C. scindens; [3], 
digested vector (pET5 l )  with the restriction enzymes; and [4], undigested vector 
(pET5 I ). 
73 
lkb 
10-
4.0-
2.0-
1.0-
Fig 38. Gel electrophoresis image of the transformants plasmid E. coli DH5a 
containing 1 2a-HSDH from Clostridiwn scindens ATCC 35704. Lane [ l ] ;  1-Kb 
DNA ladder; [ l ,  3, 5, 8, and 9]; contain the correct size of the plasmid. Product 
of 1 2a-HSDH lane [9] was sequenced and listed in (Table 6). Lanes; [2, 4, 6, 7, 
10, 1 1 , and 12] were eliminated due to the impurity. 
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Table 6. The nucleotide sequence of 1 2a-HSDH from Clostridium scindens ATCC 
35704 (NCBI Reference Sequence: NZ_DS499706. l )  
ATGGGATTTTTAACAGGTAAGACAGCCATTATCACAGGCGGGGGAAGA 
GCGACATTAAGTGACGGAAGCTGTGGTTCTATTGGCTATGGGATTGCGACC 
GCATACGCGAAAGAGGGGGCCAATCTGACCTTGACGGGACGTAATGTGAA 
GAAACTGGAAGATGCAAAAGAAGAACTGGAGAGGCTCTACGGGATTAAAG 
TGCTTGCAGTTCAGGCTGACGTAAGCGCAGGCGCTGATAATAAAGCGGTTG 
TCGAACAGGTTATTAAGCAGACAGTTGAGGAGTTTGGAAGAATTGACGTGC 
TGATTAATAATGCACAGGCATCTGCTTCAGGAGTTTCAATTGCCGATCACA 
CGACAGAGCAGTTTGACCTGGCGATTTATTCCGGGCTGTATGCGGCTTATT 
ATTATATGCAGGCGTGCTATCCGTATCTGGCAGAGGCGAAGGGAAGCGTTA 
TTAACTTTGCATCAGGCGCGGGGCTGTTCGGGCATTACGGACAATGTTCTT 
ACGCGGCAGCAAAAGAGGGTATCCGCGGTCTTACAAGAGTGGCTGCGACG 
GAGTGGGGCAAAGACGGGATTAACGTTAATGTTGTGTGTCCTCTTGCATGG 
ACAGTTCAGCTTGAGAATTTCGAGAAGGCATATCCAGATGCATTTAAAGCG 
AATGTAAAGATGCCTCCGGCCGGCCACTATGGAGATGTGGAGAAGGAAAT 
CGGACGCGTCTGTGTTCAGCTGGCATCTCCGGACTTCAAGTTCATGAGTGG 
TGAGACTATTACGCTGGAAGGCGGAATGGGGCTTAGGCCATAA 
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Characterization of the Recombinant Enzyme 12cx-HSDH. Since this study was 
chiefly dedicated to identify the conversion of 12-oxolithocholic acid to deoxycholic acid, 
it was important to continue this work with biochemical investigation to determine the 
optimal conditions for recombinant 12cx-HSDH activity. Kinetic analysis was applied for 
the recombinant enzyme from Clostridium scindens ATCC 35704. 
(i) Enzyme concentration and kinetic analysis. It was important to demonstrate the 
ideal concentration of the recombinant protein reaction. Optimal concentration of the 
recombinant 1 2a-HSDH enzyme from C. scindens was determined to be 8 nM for the 
reductive direction ( 12-oxolithochilic acid/ NADPH), V max = 33.69 ± 6.32 µmole • min·1 • 
mg·1, and for NADPH V max = 24.21 ± 2.99 µmole • min·1 • mg·1 • For the oxidative direction 
(DCA/NADP) optimal concentration for the enzyme was measured to be 10 nM, V max = 
1 16.83 ± 5.68 µmole • min·1 • mg·1, and for the NADP+ Vmax = 95.60 ± 7.46 µmole • min· 
1 • mg·1 • Optimal concentrations for both substrates and for cofactors were determined 
based on Michaelis-Menten and Lineweaver-Burk plots (Figure 39-42). Data analysis was 
finalized using Graph Pad Prism software. 
(ii) pH optimization. It was also important to vary the pH of the reaction mixture 
with all substrates and cofactors that regulate the active reaction toward each direction 
(Figure 43). pH 7.0 was determined to be the optimal for the reductive direction (12-
oxolithochilic acid/ NADPH) and pH 6.5 was the optimal for the oxidative direction 
(DCA/NADP) (Figure 43). 
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Fig 39. Biochemical characterization of recombinant 1 2cx-HSDH from Clostridium 
scindens ATCC 35704, and kinetic and Lineweaver-Burk plots of purified 12cx-HSDH 
using 1 2-oxolithocholic acid as a substrate ( 1  ). Results were the mean of three or less 
replicate experiments, values represent the means ± standard deviation (SD). 
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Fig 40. Biochemical characterization of recombinant 1 2cx.-HSDH from 
Clostridium scindens ATCC 35704, and kinetic and Lineweaver-Burk plots of 
purified 12cx.-HSDH using NADPH as a cofactor ( 1) .  Results were the mean of 
three or less replicate experiments, values represent the means ± standard 
deviation (SD). 
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Fig 41. Biochemical characterization of recombinant 12a.-HSDH from 
Clostridium scindens ATCC 35704, and kinetic and Linweaver-Burk plots of 
purified 1 2cx.-HSDH using deoxycholic acid as a substrate ( 1 ). Results were the 
mean of three or less replicate experiments, values represent the means ± standard 
deviation (SD). 
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Fig 42. Biochemical characterization of recombinant l 2a-HSDH from Clostridium 
scindens ATCC 35704, and kinetic and Lineweaver-Burk plots of purified 12a-
HSDH using NADP+ as a cofactor ( 1 ). Results were the mean of three or less 
replicate experiments, values represent the means ± standard deviation (SD). 
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Fig 43. Biochemical characterization of recombinant 12cx-HSDH from Clostridium 
scindens ATCC 35704. Optimal pH of the reductive direction: NADPH ( 1 50 µM); 
recombinant enzyme (8 nM), 12-oxoLCA (50 µM), buffering agent ( 1 50 µM); and pH 7.0 
sodium phosphate buffer (NaPi). Optimal pH of the oxidative direction: recombinant 
enzyme ( 1 0  nM); NADP+ (400 µM), DCA ( 1500 µM); buffering agent ( 150 µM); and pH 
7.5 NaPi ( l) .  Results were the mean of four or less replicate experiments, values represent 
the means ± standard deviation (SD). Symbols; •, oxidation; •,  reduction. 
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(iii) Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE). 
SDS-PAGE was applied to confirm the purity of the recombinant l 2a-HSDH enzyme from 
Clostridium scindens ATCC 35704. The enzyme was purified using Streptactin™ affinity 
chromatography (Figure 44). The recombinant enzyme 1 2a-HSDH from C. scindens 
ATCC 35704 that yielded on SDS-PAGE had a deduced subunit molecular mass of 28.2 
kDa, with an observed subunit mass of 27 .3 0.9 kDa. 
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Figure 44. Sodium Dodecyl Sulfate Polyacrylamide Gel Electrophoresis (SDS­
PAGE) of purified recombinant 12a-HSDH from Clostridium scindens ATCC 
35704. The enzyme was purified by strep-tag affinity chromatography ( 1 ) .  M; 
molecular mass marker (Bio-Rad). 
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5. DISCUSSION 
At the current study, the anaerobic bacterial strain C. scindens ATCC 35704 was found 
to actively convert 12-oxoLCA to DCA which is supported by the fact that this strain 
possess 3a-HSDH, 7a-HSDH, and 12a-HSDH (2, 4). Human gut bacteria such as 
Clostridium, Eubacterium, Bifidobacterium, and Egghertella are known to contribute to 
the occurrence of more than 20 different secondary bile acids (4). It was remarked in this 
study that C. scindens VPI 1 2708 was unable to convert the 1 2-oxoLCA to DCA, however, 
other studies have reported that C. scindens VPI 1 2708 actively converts the CA to DCA. 
Consequently, this strain was found to possess 7cx.-HSDH (5, 43). 
When 12-oxoLCA stability was observed under different conditions, such as 
incubation in sterile culture media or in spent culture media, neither condition affected the 
nature of 12-oxoLCA nor caused 1 2-oxoLCA to be converted to any other form of bile 
acids which indicate that 1 2-oxoLCA does not influence by abiotic activities. 
Despite the fact that non-induced cells of C. hylemonae were not able to produce 12-
oxoLCA from either CA or 1 2-oxoCDCA, cells induced with the CA/12-oxoCDCA 
combination generated 1 2-oxoLCA besides other oxo-derivatives, hypothetically, the 
study suggests that the pre-exposure to particular bile acid may trigger the reduction and 
oxidation reaction to produce HSDH enzymes, but, the induction mechanism is still 
unexplained( ! ,  2). Although 1 2-oxoCDCA was not transformed directly to 12-oxoLCA, 
it was transformed to 7-oxoDCA, the latter can be converted directly to 12-oxoLCA by C. 
scindens and C. hiranonis (39). Only C. scindens ATCC 35704 and C. hiranonis were able 
to transform 7-oxoDCA to DCA and 7,12-dioxoLCA to DCA, while only C. scindens 
converted the 7-oxoDCA to CA (39). Some studies were reported that, bacterial 7a-HSDH 
reactions catalyzing the bioconversion of CDCA to 7-oxoLCA, that has been reported in 
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several intestinal bacterial species, including C. scindens (44, 45). However, the 
mechanism on how this occurs is still unknown. 
Most studies were focused on the conversion of CA to DCA and CDCA to LCA by 
different anaerobic bacteria, but the current study showed that -10 oxo-bile acids 
derivatives were involved in many transformations and in the process generated several 
secondary forms in different steps (39). It was clear that different strains were causing 
different conversions in presence of the same bile acids (Figure 45). For example, C. 
scindens ATCC 35704 was the only organism found to transform 7-oxoDCA and 7,12-
dioxoLCA to CA (39). At the same time, only C. hylemonae was able to convert 7, 1 2-
dioxoLCA to 3-oxoCA. 
No activity was visualized for l2a-HSDH when CA, 3-oxoCA, 7-oxoDCA, or DCA 
were added to anaerobic cultures of C. scindens, C. hiranonis, or C. hylemonae. However, 
1 2a-HSDH activity was observed when cells were induced with CA prior to inoculate the 
cells with combination of CA and 1 2-oxoLCA, the CA induction may trigger/influence 3a, 
7a, and 1 2a-HSDH enzymes to generate several derivatives, this suggested that pre­
exposure to 12-oxoLCA or 1 2-oxoCDCA might induce HSDH activities relative to 12a­
HSDH activity but it is not reported yet if the exposure to the 1 2-oxoLCA or 1 2-oxoCDCA 
would apply to 3a- or 7a-HSDH activities (46). However, the mechanism on how this 
occurs is not clearly explained. 
As several substrates were tested to determine the potential impact of each compound 
on the transformation of 1 2-oxoLCA to DCA, each regulatory substrate tested in this 
experiment gave the same products from C. scindens metabolism. 
Although all possible products from each transformation were able to be identified and 
visualized under the UV light during the TLC process, some products were hard to identify 
85 
without examining the standard of each product on the same TLC plate. It was clear that 
TLC might not be the optimal technique to identify the presence or absence of specific 
substrates or to differentiate between related substrates. Some bile acids derivatives 
showed similar Rr values such as 3-oxoCA and 7-oxoCA, and other similarity were found 
between 1 2-oxoLCA and 3-oxoDCA, which made identification difficult; some other 
intermediate bile acids were also, for the same reason, difficult to identify (39). 
Even though, other techniques were used to determine the presence or the absence of 
bile acid such as sensitive fluorimetric assay, gas chromatography (GC), high performance 
thin-layer chromatography (HPLC) that used in clinical chemistry also used as a bile acids 
separation method, but these can only analyze either the concentration of the bile acids or 
part of bile acids due to the complex and similar structure of bile acids (47). Other 
techniques were also applied such as radioimmunoassay, bioluminescence to detect the bile 
acids, however, these were primarily used to detect diseases related to bile acids metabolize 
(47). Therefore, TLC was the suitable method to be used in this study in term of separation 
and differentiation the extractions based on the polarity of bile acids. 
Bile acids are known to be involved in food digestion, lipid and glucose regulation, 
only recently have studies shown that bile acids are much more multidimensional (44, 46). 
Bile acids can regulate host metabolic and immune functions as well as serve as a nutrient 
hormone involved with signaling within the human intestine (44, 48, 49). Deoxycholate is 
a secondary bile salt that can induce phenotypic changes in hepatic stellate cells leading to 
oversecreting of pro-inflammatory cytokines that can facilitate the development of a 
hepatocellular carcinoma( 46, 50, 5 1  ). Further studies are needed to explore the 
biochemical activities of the gut microbiota on bile acids and how these activities affect 
host physiology (9, 13). Relative Lo host physiology, bacterial contact with host epithelial 
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cells can result in the enzymatic generation of reactive oxygen species and consequent 
redox signaling. Interestingly, a recent report has demonstrated that some genera of human 
gut intestinal bacteria can induce a rapid increase of reactive oxygen species that then elicit 
a physiological response through the activation of epithelial NAPDH oxidase-1 (Nox l )  
(47). NADP-dependent 1 2a-HSDHs have been detected in Bifidobacterium species (Aries 
1 970) and C. leptum (37, 38) in Closrridium group P (37, 52), whereas NAD-dependent 
12a-HSDH activity was reported in Eggerthella lenta (53) and C. pe1fringens (37). 
Meanwhile, J 2P-HSDHs have been detected in C. tertium, C. difficile, and C. 
paraputrificum (38). 
Up to date, Clostridium group P, strain C 48-50, is the only microorganism known to 
express HSDH activity at unusually high level, meanwhile in the absence of other HSDHs 
(37). l 2a/P-HSDHs characterized to this point are constitutively expressed and non­
inducible, with the exception of the I 2P-HSDH from C. paraputrificum, which is induced 
by 12-oxo-bile acid substrates (38, 54). Generally, 12a/P-HSDHs have higher affinity for 
DCA than for CA and iso-CA(48). Together, the 12a-HSDH from C. leptwn is an 
exception, demonstrating higher affinity for CA conjugates than for free CA (45, 55). 
The reason of why C. scindens ATCC 35704, C. hiranonis DSM 13275, and C. 
hylemonae DSM 1 5053 are involved in all of these conversions to form some toxic 
products from the secondary bile acids within the bacterial environment is still unknown. 
Hypothetically, C. scindens ATCC 35704, C. hiranonis DSM 13275, and C. hylemonae 
DSM 1 5053 could benefit from the toxicity of DCA to reduce the competitors for nutrients 
in the human intestines (39). Since 1 2-oxo group of 12-oxoLCA would be expected to act 
as an electron sink for bile acids 7a-dehydroxylating bacteria, the reduction of 1 2-oxo 
group would be favorable in an anaerobic bacterial environment ( 1 ). For many years, some 
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hypothesis has suggested the benefits of bile acids contribution with the human gut 
bacteria, the first hypothesis states that some species are able to deconjugate bile acid might 
be able to use the amino acid taurine as an electron acceptor (9, 10, 14). A result that 
advocates this hypothesis was obtained for some Clostridium species ( 1 2, 24). Other 
hypothesis stated that bile acids decrease the toxicity of conjugated bile acids for bacteria 
( 19). Compared with their conjugated counterparts, deconjugated bile acids have reduced 
solubility and diminished detergent activity and may, therefore, be less toxic to bacteria in 
the intestine (6). However, further studies are still needed to comprehend the importance 
of this conversion clearly. 
In steroid metabolism, HSDH enzymes play an important role for gut bacteria. C. 
scindens ATCC 35704 was reported to express 3a-HSDH, 7a-HSDH, 20a-HSDH and 
steroid-17, 20-desmolase as part of the complex bile acid 7a-dehydroxylation pathway 
(19). The 7a-HSDH may serve two functions; i) convert 7-oxo-bile acids generated by 
other gut bacteria to ?a-hydroxy bile acids (20) and ii) regulate the flux of bile acids into 
the 7a-dehydroxylation pathway by reversible oxidation-reduction of the ?a-hydroxy 
group (34). Gut bacteria such as Clostridium baratii, B. producta , and Ruminococcus 
gnavus are also capable of forming 7P-hydroxy bile acids, including C. scindens and other 
bile acid 7-dehydroxylating bacteria circumvent this need by expressing a 7P-dehydratase 
(21 ,  22, 23). Interestingly, epimerization of the 3a-hydroxy group to 3P-hydroxy "iso-bile 
acids" prevents 7a-dehydroxylation (J. M. Ridlon and P. B. Hylemon, unpublished 
observations). C. scindens lacks 3P-HSDH, and the first enzymatic step following bile acid 
CoA-ligation is oxidation of the 3a-hydroxy group (20). Even though this study shows 
that C. scindens possess 12a-HSDH, it is not reported if C. scindens possess 12P-HSDH 
( 1 ). 1 2P-HSDHs have been detected in different members of the Firmicutes, however, up 
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to date no isolate from Clostridium has been found to possess both 1 2a- and 1 2P-HSDHs 
(57). It might be an important to understand the hypothesis of the 12-oxoLCA activity in 
the host environment, �d how that can impact the metabolism of the host secretion and 
microorganism as well. Further studies are needed to fully comprehend the hypothesis of 
the interaction between gut microbiota, host secretion, and bile acids and to determine the 
impact of these factors on steroidal bile acids transformation along with the HSDH 
enzymes activity. 
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Fig 45. Effect on structure of bile acids transformation; all mono-oxo bile acids 
derivatives that generate DCA were indicated inside the green circle, other mono-oxo 
bile acids derivatives were indicated inside the orang box, and all di/ tri-oxo bile acids 
derivatives were indicated outside the orange box. Bile acids biotransformation were 
generated by C. scindens ATCC 35704, C. hiranonis DSM 13275, and C. hylemonae 
DSM 15053. 
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